

# BreastScreen Aotearoa Monitoring **Treatment Data Report**

For Māori and Pacific women with cancers detected by BSA between July 2009 and June 2014, and Total women with cancers detected between July 2012 and June 2014, ages 45–49 and 50–69 years

A report prepared for the National Screening Unit, Ministry of Health  
by James Stanley, Bridget Robson, Lisa Kuperus  
Te Rōpū Rangahau Hauora a Eru Pōmare  
University of Otago, Wellington

8 December 2016

Prepared in December 2016 by

James Stanley, Bridget Robson, Lisa Kuperus

Te Rōpū Rangahau Hauora a Eru Pōmare  
University of Otago, Wellington  
PO Box 7343  
Wellington South  
New Zealand

For BreastScreen Aotearoa, National Screening Unit, Ministry of Health

This document is available on the National Screening Unit website [www.nsu.govt.nz](http://www.nsu.govt.nz), with an accompanying Data report on screening and assessment indicators and a narrative report on the BSA programme.

# CONTENTS

---

List of Tables .....	2
List of Figures .....	4
<b>National Profiles and Trends by Ethnicity .....</b>	<b>7</b>
National profiles .....	8
National time trends .....	11
<b>Lead Provider Profiles (Māori and Total) .....</b>	<b>21</b>
BreastScreen Waitemata and Northland (BSWN) .....	22
BreastScreen Counties Manukau (BSCM) .....	24
BreastScreen Auckland Limited (BSAL) .....	26
BreastScreen Midland (BSM) .....	28
BreastScreen Coast to Coast (BSCtoC) .....	30
BreastScreen Central (BSC) .....	32
BreastScreen South Limited (BSSL) .....	34
BreastScreen Health Care/BreastScreen Otago Southland (BSHC/BSOS) .....	36
<b>Section 3: Early detection of DCIS or invasive breast cancer .....</b>	<b>38</b>
3a.3t Treatment data completeness .....	38
3a.2 Invasive breast cancer detection .....	40
3c Invasive breast cancers less than or equal to 15mm in size .....	47
3d Nodal involvement .....	57
3e Ductal carcinoma in situ .....	64
<b>Section 4: Treatment .....</b>	<b>68</b>
4a Proportion of invasive cancers having a surgical axillary procedure .....	68
4b Proportion of invasive cancers having a single excisional procedure .....	70
4c Proportion of DCIS where no axillary dissection was carried out .....	74
4e Proportion of DCIS having breast conserving surgery .....	76
4f Proportion of invasive cancers having breast conserving surgery .....	78
4g Proportion of women with invasive cancer having radiotherapy .....	82
4h Proportion of women with DCIS having radiotherapy .....	84
4i Proportion of women with invasive cancer having chemotherapy .....	86
4j Proportion of women with invasive cancer having endocrine therapy .....	91
<b>Section 5: Provision of an appropriate and acceptable service .....</b>	<b>96</b>
5e First surgical treatment within 20 working days .....	96

## List of Tables

Table 3a.3t.a: Treatment data completeness, Māori and Pacific women aged 45–49 and 50–69 years, 5 years (July 2009–June 2014) .....	38
Table 3a.3t.b: Treatment data completeness, total women aged 45–49 and 50–69 years, 2 years (July 2012–June 2014).....	39
Table 3a.2.a: Detection rate of invasive breast cancer per 1,000 screens, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	40
Table 3a.2.b: Detection rate of invasive breast cancer per 1,000 screens, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years.....	43
Table 3a.2.c: Detection rate of invasive breast cancer per 1,000 screens, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years.....	44
Table 3c.1.a: Proportion of invasive cancers less than or equal to 15mm, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	47
Table 3c.1.b: Proportion of invasive cancers less than or equal to 15mm, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years.....	50
Table 3c.1.c: Proportion of invasive cancers less than or equal to 15mm, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years.....	51
Table 3c.2.a: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	54
Table 3c.2.b: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years....	55
Table 3c.2.c: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years.....	56
Table 3d.a: Invasive cancers without nodal involvement, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years.....	57
Table 3d.b: Invasive cancers without nodal involvement, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	60
Table 3d.c: Invasive cancers without nodal involvement, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years.....	61
Table 3e.a: Women with DCIS as a percentage of all screen detected cancers, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	64
Table 3e.b: Women with DCIS as a percentage of all screen detected cancers, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years.....	65
Table 3e.c: Women with DCIS as a percentage of all screen detected cancers, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	65
Table 4a.a: Percentage of invasive cancers having a surgical axillary procedure, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	68
Table 4a.b: Percentage of invasive cancers having a surgical axillary procedure, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years.....	69
Table 4a.c: Percentage of invasive cancers having a surgical axillary procedure, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	69
Table 4b.a: Proportion of invasive cancers having a single excisional breast treatment procedure, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	70
Table 4b.b: Proportion of invasive cancers having a single excisional breast treatment procedure, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	72
Table 4b.c: Proportion of invasive cancers having a single excisional breast treatment procedure, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years.....	72
Table 4c.a: Proportion of women with DCIS not having axillary dissection, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	74

Table 4c.b: Proportion of women with DCIS not having axillary dissection, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	75
Table 4c.c: Proportion of women with DCIS not having axillary dissection, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	75
Table 4e.a: Proportion of DCIS ≤ 20mm having BCS, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	76
Table 4e.b: Proportion of DCIS ≤ 20mm having BCS, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	77
Table 4e.c: Proportion of DCIS ≤ 20mm having BCS, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	77
Table 4f.a: Proportion of invasive cancers ≤20mm, without DCIS, having BCS, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	78
Table 4f.b: Proportion of invasive cancers ≤20mm, without DCIS, having BCS, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	80
Table 4f.c: Proportion of invasive cancers ≤20mm, without DCIS, having BCS, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	80
Table 4g.a: Proportion of invasive cancers, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	82
Table 4g.b: Proportion of invasive cancers, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	83
Table 4g.c: Proportion of invasive cancers, having BCS and having radiotherapy, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	83
Table 4h.a: Proportion of women with DCIS, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	84
Table 4h.b: Proportion of women with DCIS, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years ...	85
Table 4h.c: Proportion of women with DCIS, having BCS and having radiotherapy, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	85
Table 4i.a: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 years .....	86
Table 4i.b: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 50–69 years .....	87
Table 4i.c: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 years .....	88
Table 4i.d: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 50–69 years .....	89
Table 4i.e: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years ....	90
Table 4j.a: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 years .....	91
Table 4j.b: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 50–69 years .....	92
Table 4j.c: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 years .....	93

Table 4j.d: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 50–69 years .....	94
Table 4j.e: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years .....	95
Table 5e.a: Proportion of women receiving first surgical treatment within 20 working days, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years .....	96
Table 5e.b: Proportion of women receiving first surgical treatment within 20 working days, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years .....	98
Table 5e.c: Proportion of women receiving first surgical treatment within 20 working days, 2 years (July 2012–June 2014), total aged 45–49 and 50–69 years.....	98

## List of Figures

Figure 1: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, all BSA.....	8
Figure 2: Indicators above and below target for Pacific women aged 50 to 69 years, screened during July 2009–June 2014, all BSA.....	9
Figure 3: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, all BSA.....	10
Figure 4: National trends in the rate of detection of invasive breast cancer per 1,000 initial screens Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	11
Figure 5: National trends in the rate of detection of invasive breast cancer per 1,000 subsequent screens Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	12
Figure 6: National trends in the proportion of invasive breast cancers ≤15mm detected from initial screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	13
Figure 7: National trends in the proportion of invasive breast cancers ≤15mm detected from subsequent screens, Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	14
Figure 8: National trends in the proportion of invasive breast cancers with no nodal involvement detected from initial screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	15
Figure 9: National trends in the proportion of invasive breast cancers with no nodal involvement detected from subsequent screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	16
Figure 10: National trends in the proportion of screen-detected breast cancers that are DCIS, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014 .....	17
Figure 11: National trends in the proportion of invasive cancers having a single excisional procedure, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	18
Figure 12: National trends in the proportion of invasive cancers having breast conserving surgery, Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	19

Figure 13: National trends in the percentage of women receiving their first treatment surgery within 20 working days of receipt of the final diagnostic results, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014.....	20
Figure 14: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSWN.....	22
Figure 15: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSWN.....	23
Figure 16: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSCM.....	24
Figure 17: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSCM.....	25
Figure 18: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014 BSAL.....	26
Figure 19: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014 BSAL.....	27
Figure 20: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSM.....	28
Figure 21: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSM.....	29
Figure 22: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSCtoC.....	30
Figure 23: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSCtoC.....	31
Figure 24: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSC.....	32
Figure 25: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012 to June 2014, BSC.....	33
Figure 26: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSSL.....	34
Figure 27: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSSL.....	35
Figure 28: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSHC/BSOS.....	36
Figure 29: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSHC/BSOS.....	37
Figure 3a.2.a: Trends in the detection rate of invasive breast cancer per 1,000 initial screens, Māori and non-Māori women aged 50–69 years, by Lead Provider July 2008 to June 2014.....	41
Figure 3a.2.b: Trends in the detection rate of invasive breast cancer per 1,000 subsequent screens, Māori and non-Māori women aged 50–69 years, by Lead Provider July 2008 to June 2014.....	42
Figure 3a.2.c: Trends in the detection rate of invasive breast cancer per 1,000 initial screens, total women aged 50–69 years, by Lead Provider, July 2008 to June 2014.....	45
Figure 3a.2.d: Trends in the detection rate of invasive breast cancer per 1,000 subsequent screens, total women aged 50–69 years, by Lead Provider July 2008 to June 2014.....	46
Figure 3c.1.a Trends in the proportion of invasive breast cancers <= 15mm detected from initial screens, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014.....	48
Figure 3c.1.a Trends in the proportion of invasive breast cancers <= 15mm detected from subsequent screens, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014.....	49

Figure 3c.1.a Trends in the proportion of invasive breast cancers $\leq 15$ mm detected from initial screens, total women aged 50–69 years by Lead Provider, July 2008 to June 2014 .....	52
Figure 3c.1.b Trends in the proportion of invasive breast cancers $\leq 15$ mm detected from subsequent screens, total women aged 50–69 years by Lead Provider, July 2008 to June 2014 .....	53
Figure 3d.a Trends in the proportion of invasive breast cancers with no nodal involvement detected from an initial screen, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014.....	58
Figure 3d.b Trends in the proportion of invasive breast cancers with no nodal involvement detected from a subsequent screen, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014 .....	59
Figure 3d.c Trends in the proportion of invasive breast cancers with no nodal involvement detected from an initial screen, total women aged 50–69 years by Lead Provider, July 2008 to June 2014.....	62
Figure 3d.d Trends in the proportion of invasive breast cancers with no nodal involvement detected from a subsequent screen, total women aged 50–69 years, by Lead Provider, July 2008 to June 2014.....	63
Figure 3e.a Trends in the proportion of detected breast cancer that are DCIS, Māori and non-Māori aged 50–69 years by Lead Provider, July 2008 to June 2014.....	66
Figure 3e.b Trends in the proportion of detected breast cancer that are DCIS, total women aged 50–69 years by Lead Provider, July 2008 to June 2014 .....	67
Figure 4b.a: Trends in the proportion of invasive cancers having a single excisional procedure, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014 .....	71
Figure 4b.b: Trends in the proportion of invasive cancers having a single excisional procedure, total women aged 50–69 years by Lead Provider, July 2008 to June 2014.....	73
Figure 4f.a: Trends in the proportion of women with invasive cancers $\leq 20$ mm, without DCIS, having BCS, total women aged 50–69 years, July 2008 to June 2014.....	79
Figure 4f.b: Trends in the proportion of women with invasive cancers $\leq 20$ mm, without DCIS, having BCS, total women aged 50–69 years, July 2008 to June 2014.....	81
Figure 5e.a: Trends in the proportion of Māori and non-Māori women aged 50–69 years receiving first surgical treatment within 20 working days, by Lead Provider, July 2008–June 2014 .....	97
Figure 5e.b: Trends in the proportion of total women aged 50–69 years receiving first surgical treatment within 20 working days, by Lead Provider, July 2008–June 2014.....	99


# NATIONAL PROFILES AND TRENDS BY ETHNICITY

---


The indicators in the National Profile charts and in the Lead Provider Profiles section are all for a 5-year period for Māori and Pacific women and for a 2-year period for Total women.

## National profiles


Figure 1: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, all BSA



**Figure 2: Indicators above and below target for Pacific women aged 50 to 69 years, screened during July 2009–June 2014, all BSA**




**Figure 3: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, all BSA**



## National time trends

Figure 4: National trends in the rate of detection of invasive breast cancer per 1,000 initial screens Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014



**Figure 5: National trends in the rate of detection of invasive breast cancer per 1,000 subsequent screens Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014**




Figure 6: National trends in the proportion of invasive breast cancers  $\leq 15\text{mm}$  detected from initial screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 7: National trends in the proportion of invasive breast cancers  $\leq 15\text{mm}$  detected from subsequent screens, Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 8: National trends in the proportion of invasive breast cancers with no nodal involvement detected from initial screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 9: National trends in the proportion of invasive breast cancers with no nodal involvement detected from subsequent screens, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 10: National trends in the proportion of screen-detected breast cancers that are DCIS, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 11: National trends in the proportion of invasive cancers having a single excisional procedure, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




Figure 12: National trends in the proportion of invasive cancers having breast conserving surgery, Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014





Figure 13: National trends in the percentage of women receiving their first treatment surgery within 20 working days of receipt of the final diagnostic results, Māori, Pacific, and non-Māori non-Pacific women aged 50–69 years, July 2008 to June 2014




# LEAD PROVIDER PROFILES (MĀORI AND TOTAL)


---

## BreastScreen Waitemata and Northland (BSWN)

Figure 14: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSWN




**Figure 15: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSWN**




## BreastScreen Counties Manukau (BSCM)

Figure 16: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSCM




**Figure 17: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSCM**




## BreastScreen Auckland Limited (BSAL)

Figure 18: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014 BSAL




**Figure 19: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014 BSAL**




## BreastScreen Midland (BSM)

Figure 20: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSM




**Figure 21: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSM**




## BreastScreen Coast to Coast (BSCtoC)

Figure 22: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSCtoC




**Figure 23: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSCtoC**




## BreastScreen Central (BSC)

Figure 24: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSC




**Figure 25: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012 to June 2014, BSC**




## BreastScreen South Limited (BSSL)

Figure 26: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSSL




**Figure 27: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSSL**




## BreastScreen Health Care/BreastScreen Otago Southland (BSHC/BSOS)

Figure 28: Indicators above and below target for Māori women aged 50 to 69 years, screened during July 2009–June 2014, BSHC/BSOS



**Figure 29: Indicators above and below target for total women aged 50 to 69 years, screened during July 2012–June 2014, BSHC/BSOS**



# SECTION 3: EARLY DETECTION OF DCIS OR INVASIVE BREAST CANCER

## 3a.3† Treatment data completeness

### Description:

Lead Providers have 9 months to complete data entry for women referred to treatment.

### Target:

≥ 90%

**Table 3a.3t.a: Treatment data completeness, Māori and Pacific women aged 45–49 and 50–69 years, 5 years (July 2009–June 2014)**

Lead Provider	45–49 years								50–69 years							
	BSWN	BSCM	BSAL	BSM	BSCtoC	BSC	BSSL	BSHC/BSOS	BSWN	BSCM	BSAL	BSM	BSCtoC	BSC	BSSL	BSHC/BSOS
<b>Māori</b>																
No. of women referred for Treatment	38	30	16	37	31	13	30	7	128	109	32	196	116	65	54	17
% Staging Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Surgical Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Endocrine Complete	100	100	100	100	97	100	100	100	100	100	97	100	100	100	100	100
% Radiotherapy Complete	97	100	100	100	100	100	100	100	100	100	97	100	100	100	100	100
% Chemotherapy Complete	100	100	100	100	97	100	100	100	100	100	97	100	100	100	100	100
<b>Pacific</b>																
No. of women referred for Treatment	9	28	10	3	1	9	2	1	44	82	52	13	6	24	7	3
% Staging Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Surgical Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Endocrine Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Radiotherapy Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Chemotherapy Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100

**Table 3a.3t.b: Treatment data completeness, total women aged 45–49 and 50–69 years, 2 years (July 2012–June 2014)**

Lead Provider	45–49 years								50–69 years							
	BSWN	BSCM	BSAL	BSM	BSCtoC	BSC	BSSL	BSHC/ BSOS	BSWN	BSCM	BSAL	BSM	BSCtoC	BSC	BSSL	BSHC/ BSOS
No. of women referred for Treatment	86	58	49	63	55	54	118	41	379	226	180	405	264	211	485	164
% Staging Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Surgical Complete	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
% Endocrine Complete	100	98	100	100	98	100	100	100	100	99	99	100	100	100	100	99
% Radiotherapy Complete	98	97	100	100	100	100	100	100	100	97	99	100	100	100	100	100
% Chemotherapy Complete	100	97	100	100	98	100	100	100	100	99	99	100	100	100	100	100

### 3a.2 Invasive breast cancer detection

**Description:** The number of women who have invasive breast cancer detected within BSA, expressed as a rate per 1,000 women screened.

**Target for women aged 50–69 years:**

Initial (prevalent) round:  $\geq 6.1$  per 1,000 screens

Subsequent (incident) round:  $\geq 3.45$  per 1,000 screens

**Table 3a.2.a: Detection rate of invasive breast cancer per 1,000 screens, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/non-Māori ratio (95% CI)
	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)	
<b>45–49 years</b>							
<b>Initial screen</b>							
BSWN	19	2,992	6.4(3.8, 9.9)	73	20,967	3.5 (2.7, 4.4)	1.82 (1.10, 3.02)
BSCM	13	2,416	5.4(2.9, 9.2)	59	14,950	3.9 (3.0, 5.1)	1.36 (0.75, 2.48)
BSAL	6	976	6.1(2.3, 13.3)	39	13,831	2.8 (2.0, 3.9)	2.18 (0.93, 5.14)
BSM	22	4,031	5.5(3.4, 8.3)	52	16,386	3.2 (2.4, 4.2)	1.72 (1.05, 2.83)
BSCtoC	21	2,978	7.1(4.4, 10.8)	41	12,688	3.2 (2.3, 4.4)	2.18 (1.29, 3.69)
BSC	6	1,536	3.9(1.4, 8.5)	56	13,341	4.2 (3.2, 5.4)	0.93 (0.40, 2.16)
BSSL	12	1,762	6.8(3.5, 11.9)	60	23,257	2.6 (2.0, 3.3)	2.64 (1.42, 4.90)
BSHC/BSOS	0	673	0.0(0.0, 5.5)	33	8,581	3.8 (2.6, 5.4)	0.00 (0.00, 1.51)
<b>Total</b>	<b>99</b>	<b>17,364</b>	<b>5.7(4.6, 6.9)</b>	<b>413</b>	<b>124,001</b>	<b>3.3 (3.0, 3.7)</b>	<b>1.71 (1.38, 2.13)</b>
<b>Subsequent screen</b>							
BSWN	13	2,927	4.4(2.4, 7.6)	56	22,848	2.5 (1.9, 3.2)	1.81 (0.99, 3.31)
BSCM	9	1,785	5.0(2.3, 9.5)	27	13,821	2.0 (1.3, 2.8)	2.58 (1.22, 5.48)
BSAL	5	986	5.1(1.6, 11.8)	34	13,933	2.4 (1.7, 3.4)	2.08 (0.81, 5.30)
BSM	7	2,672	2.6(1.1, 5.4)	41	14,776	2.8 (2.0, 3.8)	0.94 (0.42, 2.10)
BSCtoC	6	2,901	2.1(0.8, 4.5)	26	16,041	1.6 (1.1, 2.4)	1.28 (0.53, 3.10)
BSC	6	1,455	4.1(1.5, 9.0)	37	13,563	2.7 (1.9, 3.8)	1.51 (0.64, 3.58)
BSSL	13	2,190	5.9(3.2, 10.1)	86	35,280	2.4 (2.0, 3.0)	2.44 (1.36, 4.36)
BSHC/BSOS	3	631	4.8(1.0, 13.8)	21	9,688	2.2 (1.3, 3.3)	2.19 (0.66, 7.33)
<b>Total</b>	<b>62</b>	<b>15,547</b>	<b>4.0(3.1, 5.1)</b>	<b>328</b>	<b>139,950</b>	<b>2.3 (2.1, 2.6)</b>	<b>1.70 (1.30, 2.23)</b>
<b>50–69 years</b>							
<b>Initial screen</b>							
BSWN	19	1,344	14.1(8.5, 22.0)	75	11,482	6.5 (5.1, 8.2)	2.16 (1.31, 3.57)
BSCM	17	1,230	13.8(8.1, 22.0)	75	9,341	8.0 (6.3, 10.1)	1.72 (1.02, 2.90)
BSAL	5	526	9.5(3.1, 22.0)	66	8,887	7.4 (5.7, 9.4)	1.28 (0.52, 3.16)
BSM	39	2,976	13.1(9.3, 17.9)	64	9,323	6.9 (5.3, 8.8)	1.91 (1.28, 2.84)
BSCtoC	25	1,929	13.0(8.4, 19.1)	46	6,620	6.9 (5.1, 9.3)	1.87 (1.15, 3.03)
BSC	12	725	16.6(8.6, 28.7)	57	6,519	8.7 (6.6, 11.3)	1.89 (1.02, 3.51)
BSSL	1	388	2.6(0.1, 14.3)	39	5,352	7.3 (5.2, 9.9)	0.35 (0.05, 2.57)
BSHC/BSOS	2	214	9.3(1.1, 33.4)	20	3,091	6.5 (4.0, 10.0)	1.44 (0.34, 6.14)
<b>Total</b>	<b>120</b>	<b>9,332</b>	<b>12.9(10.7, 15.4)</b>	<b>442</b>	<b>60,615</b>	<b>7.3 (6.6, 8.0)</b>	<b>1.76(1.44, 2.16)</b>
<b>Subsequent screen</b>							
BSWN	78	13,284	5.9(4.6, 7.3)	508	119,661	4.2 (3.9, 4.6)	1.38 (1.09, 1.75)
BSCM	80	8,330	9.6(7.6, 11.9)	267	68,148	3.9 (3.5, 4.4)	2.45 (1.91, 3.14)
BSAL	17	4,055	4.2(2.4, 6.7)	219	64,659	3.4 (3.0, 3.9)	1.24 (0.76, 2.03)
BSM	124	15,836	7.8(6.5, 9.3)	461	106,583	4.3 (3.9, 4.7)	1.81 (1.49, 2.21)
BSCtoC	76	14,043	5.4(4.3, 6.8)	395	101,569	3.9 (3.5, 4.3)	1.39 (1.09, 1.78)
BSC	38	6,544	5.8(4.1, 8.0)	320	80,619	4.0 (3.5, 4.4)	1.46 (1.05, 2.05)
BSSL	42	8,071	5.2(3.8, 7.0)	723	176,387	4.1 (3.8, 4.4)	1.27 (0.93, 1.73)
BSHC/BSOS	11	2,605	4.2(2.1, 7.5)	259	63,508	4.1 (3.6, 4.6)	1.04 (0.57, 1.89)
<b>Total</b>	<b>466</b>	<b>72,768</b>	<b>6.4(5.8, 7.0)</b>	<b>3,152</b>	<b>781,134</b>	<b>4.0 (3.9, 4.2)</b>	<b>1.59(1.44, 1.75)</b>

Target values are  $\geq 6.1$  per 1,000 initial screens and  $\geq 3.45$  per 1,000 in subsequent screens. A ratio above 1.0 shows Māori have a higher rate of screen-detected cancer than non-Māori. Ratios in italics show a statistically significant difference between Māori and non-Māori.

**Figure 3a.2.a: Trends in the detection rate of invasive breast cancer per 1,000 initial screens, Māori and non-Māori women aged 50–69 years, by Lead Provider July 2008 to June 2014**





Figure 3a.2.b: Trends in the detection rate of invasive breast cancer per 1,000 subsequent screens, Māori and non-Māori women aged 50–69 years, by Lead Provider July 2008 to June 2014



**Table 3a.2.b: Detection rate of invasive breast cancer per 1,000 screens, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/non-Māori non-Pacific ratio (95% CI)
	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)	
<b>45–49 years</b>							
<b>Initial screen</b>							
BSWN	3	1,388	2.2(0.4, 6.3)	70	19,579	3.6(2.8, 4.5)	0.60(0.19, 1.92)
BSCM	19	3,647	5.2(3.1, 8.1)	40	11,303	3.5(2.5, 4.8)	1.47(0.85, 2.54)
BSAL	5	1,813	2.8(0.9, 6.4)	34	12,018	2.8(2.0, 4.0)	0.97(0.38, 2.49)
BSM	2	323	6.2(0.8, 22.2)	50	16,063	3.1(2.3, 4.1)	1.99(0.49, 8.14)
BSCtoC	1	302	3.3(0.1, 18.3)	40	12,386	3.2(2.3, 4.4)	1.03(0.14, 7.43)
BSC	6	874	6.9(2.5, 14.9)	50	12,467	4.0(3.0, 5.3)	1.71(0.74, 3.98)
BSSL	0	323	0.0(0.0, 11.4)	60	22,934	2.6(2.0, 3.4)	0.00(0.00, 4.50)
BSHC/BSOS	0	98	0.0(0.0, 36.9)	33	8,483	3.9(2.7, 5.5)	0.00(0.00, 10.24)
<b>Total</b>	<b>36</b>	<b>8,768</b>	<b>4.1(2.9, 5.7)</b>	<b>377</b>	<b>115,233</b>	<b>3.3(3.0, 3.6)</b>	<b>1.25(0.89, 1.77)</b>
<b>Subsequent screen</b>							
BSWN	1	1,316	0.8(0.0, 4.2)	55	21,532	2.6(1.9, 3.3)	0.30(0.04, 2.15)
BSCM	3	2,644	1.1(0.2, 3.3)	24	11,177	2.1(1.4, 3.2)	0.53(0.16, 1.75)
BSAL	3	1,568	1.9(0.4, 5.6)	31	12,365	2.5(1.7, 3.6)	0.76(0.23, 2.49)
BSM	1	207	4.8(0.1, 26.6)	40	14,569	2.7(2.0, 3.7)	1.76(0.24, 12.74)
BSCtoC	0	234	0.0(0.0, 15.6)	26	15,807	1.6(1.1, 2.4)	0.00(0.00, 10.30)
BSC	0	693	0.0(0.0, 5.3)	37	12,870	2.9(2.0, 4.0)	0.00(0.00, 1.95)
BSSL	1	317	3.2(0.1, 17.4)	85	34,963	2.4(1.9, 3.0)	1.30(0.18, 9.29)
BSHC/BSOS	1	70	14.3(0.4, 77.0)	20	9,618	2.1(1.3, 3.2)	6.87(0.93, 50.49)
<b>Total</b>	<b>10</b>	<b>7,049</b>	<b>1.4(0.7, 2.6)</b>	<b>318</b>	<b>132,901</b>	<b>2.4(2.1, 2.7)</b>	<b>0.59(0.32, 1.11)</b>
<b>50–69 years</b>							
<b>Initial screen</b>							
BSWN	6	764	7.9(2.9, 17.0)	69	10,718	6.4(5.0, 8.1)	1.22(0.53, 2.80)
BSCM	18	2,168	8.3(4.9, 13.1)	57	7,173	7.9(6.0, 10.3)	1.04(0.62, 1.77)
BSAL	11	1,011	10.9(5.4, 19.4)	55	7,876	7.0(5.3, 9.1)	1.56(0.82, 2.97)
BSM	0	237	0.0(0.0, 15.4)	64	9,086	7.0(5.4, 9.0)	0.00(0.00, 2.27)
BSCtoC	3	190	15.8(3.3, 45.4)	43	6,430	6.7(4.8, 9.0)	2.36(0.74, 7.54)
BSC	6	585	10.3(3.8, 22.2)	51	5,934	8.6(6.4, 11.3)	1.19(0.51, 2.77)
BSSL	0	102	0.0(0.0, 35.5)	39	5,250	7.4(5.3, 10.1)	0.00(0.00, 5.11)
BSHC/BSOS	1	51	19.6(0.5, 104.5)	19	3,040	6.2(3.8, 9.7)	3.14(0.43, 22.99)
<b>Total</b>	<b>45</b>	<b>5,108</b>	<b>8.8(6.4, 11.8)</b>	<b>397</b>	<b>55,507</b>	<b>7.2(6.5, 7.9)</b>	<b>1.23(0.91, 1.67)</b>
<b>Subsequent screen</b>							
BSWN	24	5,539	4.3(2.8, 6.4)	484	114,122	4.2(3.9, 4.6)	1.02(0.68, 1.54)
BSCM	38	11,578	3.3(2.3, 4.5)	229	56,570	4.0(3.5, 4.6)	0.81(0.58, 1.14)
BSAL	26	6,507	4.0(2.6, 5.8)	193	58,152	3.3(2.9, 3.8)	1.20(0.80, 1.81)
BSM	11	1,220	9.0(4.5, 16.1)	450	105,363	4.3(3.9, 4.7)	2.11(1.16, 3.83)
BSCtoC	2	1,108	1.8(0.2, 6.5)	393	100,461	3.9(3.5, 4.3)	0.46(0.12, 1.85)
BSC	12	3,544	3.4(1.8, 5.9)	308	77,075	4.0(3.6, 4.5)	0.85(0.48, 1.51)
BSSL	7	1,229	5.7(2.3, 11.7)	716	175,158	4.1(3.8, 4.4)	1.39(0.66, 2.93)
BSHC/BSOS	1	320	3.1(0.1, 17.3)	258	63,188	4.1(3.6, 4.6)	0.77(0.11, 5.44)
<b>Total</b>	<b>121</b>	<b>31,045</b>	<b>3.9(3.2, 4.7)</b>	<b>3,031</b>	<b>750,089</b>	<b>4.0(3.9, 4.2)</b>	<b>0.96(0.80, 1.16)</b>

Target values are  $\geq 6.1$  per 1,000 initial screens and  $\geq 3.45$  per 1,000 in subsequent screens.

A ratio above 1.0 shows Pacific women have a higher rate of screen-detected cancer than non-Māori non-Pacific women. Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women.

Table 3a.2.c: Detection rate of invasive breast cancer per 1,000 screens, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years

Lead provider	45–49 years			50–69 years		
	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)	Number with breast cancer	Number of screens	Rate of breast cancers detected per 1,000 screens (95% CI)
<b>Initial screen</b>						
BSWN	39	8,814	4.4(3.1, 6.0)	15	3,756	4.0 (2.2, 6.6)
BSCM	25	6,502	3.8(2.5, 5.7)	26	3,173	8.2 (5.4, 12.0)
BSAL	17	5,895	2.9(1.7, 4.6)	24	3,137	7.7 (4.9, 11.4)
BSM	30	8,035	3.7(2.5, 5.3)	43	4,538	9.5 (6.9, 12.7)
BSCtoC	28	5,890	4.8(3.2, 6.9)	22	2,586	8.5 (5.3, 12.9)
BSC	22	5,702	3.9(2.4, 5.8)	19	2,355	8.1 (4.9, 12.6)
BSSL	34	9,908	3.4(2.4, 4.8)	11	2,008	5.5 (2.7, 9.8)
BSHC/BSOS	19	4,459	4.3(2.6, 6.6)	11	1,355	8.1 (4.1, 14.5)
<b>Total</b>	<b>214</b>	<b>55,205</b>	<b>3.9(3.4, 4.4)</b>	<b>171</b>	<b>22,908</b>	<b>7.5 (6.4, 8.7)</b>
<b>Subsequent screen</b>						
BSWN	26	10,717	2.4(1.6, 3.6)	262	55,961	4.7 (4.1, 5.3)
BSCM	21	7,274	2.9(1.8, 4.4)	145	34,107	4.3 (3.6, 5.0)
BSAL	14	6,812	2.1(1.1, 3.4)	106	31,070	3.4 (2.8, 4.1)
BSM	16	7,577	2.1(1.2, 3.4)	276	53,152	5.2 (4.6, 5.8)
BSCtoC	14	8,029	1.7(1.0, 2.9)	199	50,877	3.9 (3.4, 4.5)
BSC	21	6,246	3.4(2.1, 5.1)	139	36,612	3.8 (3.2, 4.5)
BSSL	49	14,825	3.3(2.4, 4.4)	364	75,420	4.8 (4.3, 5.3)
BSHC/BSOS	5	4,004	1.2(0.4, 2.9)	123	28,038	4.4 (3.6, 5.2)
<b>Total</b>	<b>166</b>	<b>65,484</b>	<b>2.5(2.2, 3.0)</b>	<b>1,614</b>	<b>365,237</b>	<b>4.4 (4.2, 4.6)</b>

Target values are  $\geq 6.1$  per 1,000 initial screens and  $\geq 3.45$  per 1,000 in subsequent screens for women aged 50 – 69 years.

**Figure 3a.2.c: Trends in the detection rate of invasive breast cancer per 1,000 initial screens, total women aged 50–69 years, by Lead Provider, July 2008 to June 2014**





Figure 3a.2.d: Trends in the detection rate of invasive breast cancer per 1,000 subsequent screens, total women aged 50–69 years, by Lead Provider July 2008 to June 2014



### 3c Invasive breast cancers less than or equal to 15mm in size

**Description:** Rate and proportion of primary invasive breast cancer of diameter ≤15mm.

**Target for women aged 50–69 years:**

Initial (prevalent) round: >50%, which gives a rate of >30.5 per 10,000 women screened.


Subsequent (incident) round: >50%, which gives a rate of > 17.3 per 10,000 women screened

**Table 3c.1.a: Proportion of invasive cancers less than or equal to 15mm, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**


Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers ≤15mm	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers <15mm	
<b>45–49 years</b>							
<b>Initial screens</b>							
BSWN	14	19	73.7(48.8, 90.9)	44	71	62.0(49.7, 73.2)	1.19(0.86, 1.65)
BSCM	3	12	25.0(5.5, 57.2)	26	57	45.6(32.4, 59.3)	0.55(0.20, 1.52)
BSAL	2	6	33.3(4.3, 77.7)	19	38	50.0(33.4, 66.6)	0.67(0.21, 2.16)
BSM	13	22	59.1(36.4, 79.3)	27	49	55.1(40.2, 69.3)	1.07(0.70, 1.65)
BSCtoC	10	21	47.6(25.7, 70.2)	22	41	53.7(37.4, 69.3)	0.89(0.52, 1.51)
BSC	1	6	16.7(0.4, 64.1)	31	54	57.4(43.2, 70.8)	0.29(0.05, 1.76)
BSSL	8	12	66.7(34.9, 90.1)	29	58	50.0(36.6, 63.4)	1.33(0.83, 2.15)
BSHC/BSOS	0	0		23	33	69.7(51.3, 84.4)	
<b>Total</b>	<b>51</b>	<b>98</b>	<b>52.0(41.7, 62.2)</b>	<b>221</b>	<b>401</b>	<b>55.1(50.1, 60.1)</b>	<b>0.94(0.77, 1.16)</b>
<b>Subsequent screens</b>							
BSWN	8	13	61.5(31.6, 86.1)	38	55	69.1(55.2, 80.9)	0.89(0.56, 1.42)
BSCM	4	9	44.4(13.7, 78.8)	11	27	40.7(22.4, 61.2)	1.09(0.46, 2.58)
BSAL	3	5	60.0(14.7, 94.7)	20	34	58.8(40.7, 75.4)	1.02(0.47, 2.20)
BSM	2	7	28.6(3.7, 71.0)	25	41	61.0(44.5, 75.8)	0.47(0.14, 1.55)
BSCtoC	1	6	16.7(0.4, 64.1)	11	26	42.3(23.4, 63.1)	0.39(0.06, 2.49)
BSC	5	5	100.0(47.8, 100.0)	21	37	56.8(39.5, 72.9)	1.76(0.92, 2.23) #
BSSL	10	13	76.9(46.2, 95.0)	50	84	59.5(48.3, 70.1)	1.29(0.91, 1.83)
BSHC/BSOS	2	3	66.7(9.4, 99.2)	9	20	45.0(23.1, 68.5)	1.48(0.58, 3.78)
<b>Total</b>	<b>35</b>	<b>61</b>	<b>57.4(44.1, 70.0)</b>	<b>185</b>	<b>324</b>	<b>57.1(51.5, 62.6)</b>	<b>1.00(0.79, 1.27)</b>
<b>50–69 years</b>							
<b>Initial screens</b>							
BSWN	13	19	68.4(43.4, 87.4)	52	75	69.3(57.6, 79.5)	0.99(0.70, 1.39)
BSCM	10	17	58.8(32.9, 81.6)	33	72	45.8(34.0, 58.0)	1.28(0.80, 2.05)
BSAL	1	5	20.0(0.5, 71.6)	42	65	64.6(51.8, 76.1)	0.31(0.05, 1.80)
BSM	22	39	56.4(39.6, 72.2)	32	63	50.8(37.9, 63.6)	1.11(0.77, 1.60)
BSCtoC	10	25	40.0(21.1, 61.3)	24	46	52.2(36.9, 67.1)	0.77(0.44, 1.33)
BSC	7	11	63.6(30.8, 89.1)	30	56	53.6(39.7, 67.0)	1.19(0.71, 1.98)
BSSL	1	1	100.0(2.5, 100.0)	21	39	53.8(37.2, 69.9)	1.86(0.29, 2.19) #
BSHC/BSOS	1	2	50.0(1.3, 98.7)	9	20	45.0(23.1, 68.5)	1.11(0.26, 4.82)
<b>Total</b>	<b>65</b>	<b>119</b>	<b>54.6(45.2, 63.8)</b>	<b>243</b>	<b>436</b>	<b>55.7(50.9, 60.5)</b>	<b>0.98(0.82, 1.18)</b>
<b>Subsequent screens</b>							
BSWN	53	78	67.9(56.4, 78.1)	348	507	68.6(64.4, 72.7)	0.99(0.84, 1.17)
BSCM	50	80	62.5(51.0, 73.1)	137	266	51.5(45.3, 57.7)	1.21(0.99, 1.49)
BSAL	6	17	35.3(14.2, 61.7)	126	214	58.9(52.0, 65.5)	0.60(0.31, 1.15)
BSM	77	124	62.1(52.9, 70.7)	303	453	66.9(62.3, 71.2)	0.93(0.80, 1.08)
BSCtoC	44	76	57.9(46.0, 69.1)	235	392	59.9(54.9, 64.8)	0.97(0.78, 1.19)
BSC	26	37	70.3(53.0, 84.1)	194	317	61.2(55.6, 66.6)	1.15(0.91, 1.44)
BSSL	33	42	78.6(63.2, 89.7)	521	718	72.6(69.1, 75.8)	1.08(0.92, 1.28)
BSHC/BSOS	6	11	54.5(23.4, 83.3)	171	256	66.8(60.7, 72.5)	0.82(0.47, 1.41)
<b>Total</b>	<b>295</b>	<b>465</b>	<b>63.4(58.9, 67.8)</b>	<b>2,035</b>	<b>3,123</b>	<b>65.2(63.5, 66.8)</b>	<b>0.97(0.90, 1.05)</b>

Ratios below one are unfavourable to Māori. Target values are >50% for both initial and subsequent screens.

Figure 3c.1.a Trends in the proportion of invasive breast cancers  $\leq 15\text{mm}$  detected from initial screens, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014



**Figure 3c.1.a Trends in the proportion of invasive breast cancers <= 15mm detected from subsequent screens, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Table 3c.1.b: Proportion of invasive cancers less than or equal to 15mm, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers ≤15mm	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers ≤15mm	
<b>45–49 years</b>							
<b>Initial screens</b>							
BSWN	2	3	66.7(9.4, 99.2)	42	68	61.8(49.2, 73.3)	1.08(0.47, 2.45)
BSCM	3	17	17.6(3.8, 43.4)	23	40	57.5(40.9, 73.0)	0.31(0.11, 0.89)
BSAL	2	5	40.0(5.3, 85.3)	17	33	51.5(33.5, 69.2)	0.78(0.25, 2.39)
BSM	0	2	0.0(0.0, 84.2)	27	47	57.4(42.2, 71.7)	0.00(0.00, 3.44)
BSCtoC	1	1	100.0(2.5, 100.0)	21	40	52.5(36.1, 68.5)	1.90(0.30, 2.25) #
BSC	1	5	20.0(0.5, 71.6)	30	49	61.2(46.2, 74.8)	0.33(0.06, 1.91)
BSSL	0	0	-	29	58	50.0(36.6, 63.4)	-
BSHC/BSOS	0	0	-	23	33	69.7(51.3, 84.4)	-
<b>Total</b>	<b>9</b>	<b>33</b>	<b>27.3(13.3, 45.5)</b>	<b>212</b>	<b>368</b>	<b>57.6(52.4, 62.7)</b>	<b>0.47(0.27, 0.83)</b>
<b>Subsequent screens</b>							
BSWN	1	1	100.0(2.5, 100.0)	37	54	68.5(54.4, 80.5)	1.46(0.23, 1.58) #
BSCM	1	3	33.3(0.8, 90.6)	10	24	41.7(22.1, 63.4)	0.80(0.15, 4.24)
BSAL	3	3	100.0(29.2, 100.0)	17	31	54.8(36.0, 72.7)	1.82(0.70, 2.34) #
BSM	0	1	0.0(0.0, 97.5)	25	40	62.5(45.8, 77.3)	0.00(0.00, 6.36)
BSCtoC	0	0	-	11	26	42.3(23.4, 63.1)	-
BSC	0	0	-	21	37	56.8(39.5, 72.9)	-
BSSL	0	1	0.0(0.0, 97.5)	50	83	60.2(48.9, 70.8)	0.00(0.00, 6.36)
BSHC/BSOS	0	1	0.0(0.0, 97.5)	9	19	47.4(24.4, 71.1)	0.00(0.00, 9.63)
<b>Total</b>	<b>5</b>	<b>10</b>	<b>50.0(18.7, 81.3)</b>	<b>180</b>	<b>314</b>	<b>57.3(51.6, 62.9)</b>	<b>0.87(0.47, 1.63)</b>
<b>50–69 years</b>							
<b>Initial screens</b>							
BSWN	2	6	33.3(4.3, 77.7)	50	69	72.5(60.4, 82.5)	0.46(0.15, 1.44)
BSCM	9	17	52.9(27.8, 77.0)	24	55	43.6(30.3, 57.7)	1.21(0.71, 2.08)
BSAL	6	10	60.0(26.2, 87.8)	36	55	65.5(51.4, 77.8)	0.92(0.53, 1.57)
BSM	0	0	-	32	63	50.8(37.9, 63.6)	-
BSCtoC	0	3	0.0(0.0, 70.8)	24	43	55.8(39.9, 70.9)	0.00(0.00, 2.38)
BSC	1	6	16.7(0.4, 64.1)	29	50	58.0(43.2, 71.8)	0.29(0.05, 1.75)
BSSL	0	0	-	21	39	53.8(37.2, 69.9)	-
BSHC/BSOS	0	1	0.0(0.0, 97.5)	9	19	47.4(24.4, 71.1)	0.00(0.00, 9.63)
<b>Total</b>	<b>18</b>	<b>43</b>	<b>41.9(27.0, 57.9)</b>	<b>225</b>	<b>393</b>	<b>57.3(52.2, 62.2)</b>	<b>0.73(0.51, 1.05)</b>
<b>Subsequent screens</b>							
BSWN	17	24	70.8(48.9, 87.4)	331	483	68.5(64.2, 72.7)	1.03(0.79, 1.35)
BSCM	15	38	39.5(24.0, 56.6)	122	228	53.5(46.8, 60.1)	0.74(0.49, 1.11)
BSAL	11	24	45.8(25.6, 67.2)	115	190	60.5(53.2, 67.5)	0.76(0.48, 1.19)
BSM	6	11	54.5(23.4, 83.3)	297	442	67.2(62.6, 71.6)	0.81(0.47, 1.40)
BSCtoC	1	2	50.0(1.3, 98.7)	234	390	60.0(54.9, 64.9)	0.83(0.21, 3.34)
BSC	6	12	50.0(21.1, 78.9)	188	305	61.6(55.9, 67.1)	0.81(0.46, 1.44)
BSSL	5	7	71.4(29.0, 96.3)	516	711	72.6(69.1, 75.8)	0.98(0.61, 1.58)
BSHC/BSOS	1	1	100.0(2.5, 100.0)	170	255	66.7(60.5, 72.4)	1.50(0.24, 1.52) #
<b>Total</b>	<b>62</b>	<b>119</b>	<b>52.1(42.8, 61.3)</b>	<b>1,973</b>	<b>3,004</b>	<b>65.7(63.9, 67.4)</b>	<b>0.79(0.67, 0.94)</b>


Ratios below one are unfavourable to Pacific women. Target values are >50% for both initial and subsequent screens. . Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women.

**Table 3c.1.c: Proportion of invasive cancers less than or equal to 15mm, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**


Lead provider	45–49 years			50–69 years		
	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers ≤15mm	Invasive cancers ≤15mm	Total invasive cancers	% of invasive cancers ≤15mm
<b>Initial screens</b>						
BSWN	23	37	62.2(44.8, 77.5)	8	15	53.3(26.6, 78.7)
BSCM	12	25	48.0(27.8, 68.7)	7	24	29.2(12.6, 51.1)
BSAL	10	17	58.8(32.9, 81.6)	13	23	56.5(34.5, 76.8)
BSM	16	29	55.2(35.7, 73.6)	20	43	46.5(31.2, 62.3)
BSCtoC	19	28	67.9(47.6, 84.1)	10	22	45.5(24.4, 67.8)
BSC	11	20	55.0(31.5, 76.9)	12	19	63.2(38.4, 83.7)
BSSL	19	33	57.6(39.2, 74.5)	9	11	81.8(48.2, 97.7)
BSHC/BSOS	11	19	57.9(33.5, 79.7)	5	11	45.5(16.7, 76.6)
<b>Total</b>	<b>121</b>	<b>208</b>	<b>58.2(51.2, 65.0)</b>	<b>84</b>	<b>168</b>	<b>50.0(42.2, 57.8)</b>
<b>Subsequent screens</b>						
BSWN	15	25	60.0(38.7, 78.9)	167	261	64.0(57.8, 69.8)
BSCM	8	21	38.1(18.1, 61.6)	73	144	50.7(42.2, 59.1)
BSAL	6	14	42.9(17.7, 71.1)	59	102	57.8(47.7, 67.6)
BSM	9	16	56.2(29.9, 80.2)	167	271	61.6(55.5, 67.4)
BSCtoC	3	14	21.4(4.7, 50.8)	118	198	59.6(52.4, 66.5)
BSC	14	20	70.0(45.7, 88.1)	80	137	58.4(49.7, 66.7)
BSSL	31	48	64.6(49.5, 77.8)	266	359	74.1(69.2, 78.6)
BSHC/BSOS	3	5	60.0(14.7, 94.7)	80	122	65.6(56.4, 73.9)
<b>Total</b>	<b>89</b>	<b>163</b>	<b>54.6(46.6, 62.4)</b>	<b>1,010</b>	<b>1,594</b>	<b>63.4(60.9, 65.7)</b>

Target values are >50% for both initial and subsequent screens.

Figure 3c.1.a Trends in the proportion of invasive breast cancers <= 15mm detected from initial screens, total women aged 50–69 years by Lead Provider, July 2008 to June 2014



**Figure 3c.1.b Trends in the proportion of invasive breast cancers <= 15mm detected from subsequent screens, total women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Table 3c.2.a: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/non-Māori ratio (95% CI)
	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens	
<b>45–49 years</b>							
<b>Initial screen</b>							
BSWN	14	2,992	46.8(25.6, 78.4)	44	20,964	21.0 (15.3, 28.2)	2.23(1.22, 4.06)
BSCM	3	2,415	12.4(2.6, 36.3)	26	14,948	17.4 (11.4, 25.5)	0.71(0.22, 2.36)
BSAL	2	976	20.5(2.5, 73.8)	19	13,829	13.7 (8.3, 21.4)	1.49(0.35, 6.39)
BSM	13	4,031	32.3(17.2, 55.1)	27	16,383	16.5 (10.9, 24.0)	1.96(1.01, 3.79)
BSCtoC	10	2,978	33.6(16.1, 61.7)	22	12,688	17.3 (10.9, 26.2)	1.94(0.92, 4.09)
BSC	1	1,536	6.5(0.2, 36.2)	31	13,339	23.2 (15.8, 33.0)	0.28(0.04, 2.05)
BSSL	8	1,762	45.4(19.6, 89.3)	29	23,255	12.5 (8.4, 17.9)	3.64(1.67, 7.95)
BSHC/BSOS	0	673	0.0(0.0, 54.7)	23	8,581	26.8 (17.0, 40.2)	0.00(0.00, 2.22)
<b>Total</b>	<b>51</b>	<b>17,363</b>	<b>29.4(21.9, 38.6)</b>	<b>221</b>	<b>123,987</b>	<b>17.8 (15.6, 20.3)</b>	<b>1.65(1.22, 2.23)</b>
<b>Subsequent screen</b>							
BSWN	8	2,927	27.3(11.8, 53.8)	38	22,847	16.6 (11.8, 22.8)	1.64(0.77, 3.52)
BSCM	4	1,785	22.4(6.1, 57.3)	11	13,821	8.0 (4.0, 14.2)	2.82(0.90, 8.83)
BSAL	3	986	30.4(6.3, 88.7)	20	13,933	14.4 (8.8, 22.2)	2.12(0.63, 7.12)
BSM	2	2,672	7.5(0.9, 27.0)	25	14,776	16.9 (11.0, 25.0)	0.44(0.10, 1.87)
BSCtoC	1	2,901	3.4(0.1, 19.2)	11	16,041	6.9 (3.4, 12.3)	0.50(0.06, 3.89)
BSC	5	1,454	34.4(11.2, 80.1)	21	13,563	15.5 (9.6, 23.7)	2.22(0.84, 5.88)
BSSL	10	2,189	45.7(21.9, 83.9)	50	35,278	14.2 (10.5, 18.7)	3.22(1.64, 6.35)
BSHC/BSOS	2	631	31.7(3.8, 114.0)	9	9,687	9.3 (4.2, 17.6)	3.41(0.74, 15.76)
<b>Total</b>	<b>35</b>	<b>15,545</b>	<b>22.5(15.7, 31.3)</b>	<b>185</b>	<b>139,946</b>	<b>13.2 (11.4, 15.3)</b>	<b>1.70(1.19, 2.44)</b>
<b>50–69 years</b>							
<b>Initial screen</b>							
BSWN	13	1,344	96.7(51.6, 164.8)	52	11,482	45.3(33.8, 59.3)	2.14(1.17, 3.91)
BSCM	10	1,230	81.3(39.1, 149.0)	33	9,338	35.3(24.3, 49.6)	2.30(1.14, 4.66)
BSAL	1	526	19.0(0.5, 105.5)	42	8,885	47.3(34.1, 63.8)	0.40(0.06, 2.92)
BSM	22	2,976	73.9(46.4, 111.7)	32	9,322	34.3(23.5, 48.4)	2.15(1.25, 3.70)
BSCtoC	10	1,929	51.8(24.9, 95.1)	24	6,620	36.3(23.2, 53.9)	1.43(0.69, 2.98)
BSC	7	724	96.7(39.0, 198.2)	30	6,518	46.0(31.1, 65.6)	2.10(0.93, 4.77)
BSSL	1	388	25.8(0.7, 142.8)	21	5,352	39.2(24.3, 59.9)	0.66(0.09, 4.87)
BSHC/BSOS	1	214	46.7(1.2, 257.6)	9	3,091	29.1(13.3, 55.2)	1.60(0.20, 12.61)
<b>Total</b>	<b>65</b>	<b>9,331</b>	<b>69.7(53.8, 88.7)</b>	<b>243</b>	<b>60,608</b>	<b>40.1(35.2, 45.5)</b>	<b>1.74(1.32, 2.28)</b>
<b>Subsequent screen</b>							
BSWN	53	13,284	39.9(29.9, 52.2)	348	119,659	29.1(26.1, 32.3)	1.37(1.03, 1.83)
BSCM	50	8,330	60.0(44.6, 79.1)	137	68,147	20.1(16.9, 23.8)	2.99(2.16, 4.12)
BSAL	6	4,055	14.8(5.4, 32.2)	126	64,651	19.5(16.2, 23.2)	0.76(0.33, 1.72)
BSM	77	15,836	48.6(38.4, 60.7)	303	106,575	28.4(25.3, 31.8)	1.71(1.33, 2.20)
BSCtoC	44	14,043	31.3(22.8, 42.0)	235	101,566	23.1(20.3, 26.3)	1.35(0.98, 1.87)
BSC	26	6,543	39.7(26.0, 58.2)	194	80,616	24.1(20.8, 27.7)	1.65(1.10, 2.48)
BSSL	33	8,071	40.9(28.2, 57.4)	521	176,382	29.5(27.1, 32.2)	1.38(0.97, 1.97)
BSHC/BSOS	6	2,605	23.0(8.5, 50.1)	171	63,503	26.9(23.0, 31.3)	0.86(0.38, 1.93)
<b>Total</b>	<b>295</b>	<b>72,767</b>	<b>40.5(36.1, 45.4)</b>	<b>2,035</b>	<b>781,099</b>	<b>26.1(24.9, 27.2)</b>	<b>1.56(1.38, 1.76)</b>

Ratios above 1 mean Māori have higher rates of screen detected cancer ≤15mm than non-Māori. Ratios in italics show a statistically significant difference between Māori and non-Māori. Target values are ≥ 30.5 per 10,000 screens for initial screens and ≥17.3 per 10,000 screens for subsequent screens.

**Table 3c.2.b: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/non-Māori non-Pacific ratio (95% CI)
	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens (95% CI)	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens (95% CI)	
<b>45–49 years</b>							
<b>Initial screen</b>							
BSWN	2	1,387	14.4(1.7, 52.0)	42	19,577	21.5(15.5, 29.0)	0.67(0.16, 2.77)
BSCM	3	3,645	8.2(1.7, 24.0)	23	11,303	20.3(12.9, 30.5)	0.40(0.12, 1.35)
BSAL	2	1,813	11.0(1.3, 39.8)	17	12,016	14.1(8.2, 22.6)	0.78(0.18, 3.37)
BSM	0	323	0.0(0.0, 113.6)	27	16,060	16.8(11.1, 24.5)	0.00(0.00, 7.28)
BSCtoC	1	302	33.1(0.8, 183.1)	21	12,386	17.0(10.5, 25.9)	1.95(0.26, 14.47)
BSC	1	873	11.5(0.3, 63.7)	30	12,466	24.1(16.2, 34.3)	0.48(0.06, 3.49)
BSSL	0	323	0.0(0.0, 113.6)	29	22,932	12.6(8.5, 18.2)	0.00(0.00, 9.63)
BSHC/BSOS	0	98	0.0(0.0, 369.4)	23	8,483	27.1(17.2, 40.7)	0.00(0.00, 15.06)
<b>Total</b>	<b>9</b>	<b>8,764</b>	<b>10.3(4.7, 19.5)</b>	<b>212</b>	<b>115,223</b>	<b>18.4(16.0, 21.0)</b>	<b>0.56(0.29, 1.09)</b>
<b>Subsequent screen</b>							
BSWN	1	1,316	7.6(0.2, 42.3)	37	21,531	17.2(12.1, 23.7)	0.44(0.06, 3.22)
BSCM	1	2,644	3.8(0.1, 21.1)	10	11,177	8.9(4.3, 16.4)	0.42(0.05, 3.30)
BSAL	3	1,568	19.1(3.9, 55.8)	17	12,365	13.7(8.0, 22.0)	1.39(0.41, 4.74)
BSM	0	207	0.0(0.0, 176.6)	25	14,569	17.2(11.1, 25.3)	0.00(0.00, 11.19)
BSCtoC	0	234	0.0(0.0, 156.4)	11	15,807	7.0(3.5, 12.4)	0.00(0.00, 26.91)
BSC	0	693	0.0(0.0, 53.1)	21	12,870	16.3(10.1, 24.9)	0.00(0.00, 3.57)
BSSL	0	317	0.0(0.0, 115.7)	50	34,961	14.3(10.6, 18.9)	0.00(0.00, 8.44)
BSHC/BSOS	0	70	0.0(0.0, 513.3)	9	9,617	9.4(4.3, 17.8)	0.00(0.00, 69.60)
<b>Total</b>	<b>5</b>	<b>7,049</b>	<b>7.1(2.3, 16.5)</b>	<b>180</b>	<b>132,897</b>	<b>13.5(11.6, 15.7)</b>	<b>0.52(0.22, 1.27)</b>
<b>50–69 years</b>							
<b>Initial screen</b>							
BSWN	2	764	26.2(3.2, 94.2)	50	10,718	46.7(34.6, 61.5)	0.56(0.14, 2.30)
BSCM	9	2,167	41.5(19.0, 78.7)	24	7,171	33.5(21.5, 49.8)	1.24(0.58, 2.67)
BSAL	6	1,009	59.5(21.9, 129.0)	36	7,876	45.7(32.0, 63.2)	1.30(0.55, 3.08)
BSM	0	237	0.0(0.0, 154.4)	32	9,085	35.2(24.1, 49.7)	0.00(0.00, 4.68)
BSCtoC	0	190	0.0(0.0, 192.3)	24	6,430	37.3(23.9, 55.5)	0.00(0.00, 5.62)
BSC	1	585	17.1(0.4, 94.9)	29	5,933	48.9(32.8, 70.1)	0.35(0.05, 2.56)
BSSL	0	102	0.0(0.0, 355.2)	21	5,250	40.0(24.8, 61.1)	0.00(0.00, 9.88)
BSHC/BSOS	0	51	0.0(0.0, 697.8)	9	3,040	29.6(13.5, 56.1)	0.00(0.00, 30.20)
<b>Total</b>	<b>18</b>	<b>5,105</b>	<b>35.3(20.9, 55.7)</b>	<b>225</b>	<b>55,503</b>	<b>40.5(35.4, 46.2)</b>	<b>0.87(0.54, 1.40)</b>
<b>Subsequent screen</b>							
BSWN	17	5,539	30.7(17.9, 49.1)	331	114,120	29.0(26.0, 32.3)	1.06(0.65, 1.72)
BSCM	15	11,578	13.0(7.3, 21.4)	122	56,569	21.6(17.9, 25.7)	0.60(0.35, 1.03)
BSAL	11	6,505	16.9(8.4, 30.2)	115	58,146	19.8(16.3, 23.7)	0.86(0.46, 1.59)
BSM	6	1,220	49.2(18.1, 106.7)	297	105,355	28.2(25.1, 31.6)	1.74(0.78, 3.91)
BSCtoC	1	1,108	9.0(0.2, 50.2)	234	100,458	23.3(20.4, 26.5)	0.39(0.05, 2.76)
BSC	6	3,544	16.9(6.2, 36.8)	188	77,072	24.4(21.0, 28.1)	0.69(0.31, 1.56)
BSSL	5	1,229	40.7(13.2, 94.7)	516	175,153	29.5(27.0, 32.1)	1.38(0.57, 3.33)
BSHC/BSOS	1	320	31.2(0.8, 172.9)	170	63,183	26.9(23.0, 31.3)	1.16(0.16, 8.27)
<b>Total</b>	<b>62</b>	<b>31,043</b>	<b>20.0(15.3, 25.6)</b>	<b>1,973</b>	<b>750,056</b>	<b>26.3(25.2, 27.5)</b>	<b>0.76(0.59, 0.98)</b>

Ratios above 1 mean Pacific women have higher rates of screen detected cancer ≤15mm than non-Māori non-Pacific women. Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women. Target values are ≥ 30.5 per 10,000 screens for initial screens and ≥17.3 per 10,000 screens for subsequent screens.

Table 3c.2.c: Rate of invasive cancers less than or equal to 15mm, per 10,000 screens, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years

Lead provider	45–49 years			50–69 years		
	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens (95% CI)	Invasive cancers ≤15mm	Number of screens	Number of invasive cancers ≤15mm per 10,000 screens (95% CI)
<b>Initial screen</b>						
BSWN	23	8,811	26.1(16.6, 39.1)	8	3,756	21.3 (9.2, 41.9)
BSCM	12	6,502	18.5(9.5, 32.2)	7	3,171	22.1 (8.9, 45.4)
BSAL	10	5,895	17.0(8.1, 31.2)	13	3,136	41.5 (22.1, 70.8)
BSM	16	8,034	19.9(11.4, 32.3)	20	4,538	44.1 (26.9, 68.0)
BSCtoC	19	5,890	32.3(19.4, 50.3)	10	2,586	38.7 (18.6, 71.0)
BSC	11	5,700	19.3(9.6, 34.5)	12	2,355	51.0 (26.4, 88.8)
BSSL	19	9,907	19.2(11.6, 29.9)	9	2,008	44.8 (20.5, 84.9)
BSHC/BSOS	11	4,459	24.7(12.3, 44.1)	5	1,355	36.9 (12.0, 85.9)
<b>Total</b>	<b>121</b>	<b>55,198</b>	<b>21.9(18.2, 26.2)</b>	<b>84</b>	<b>22,905</b>	<b>36.7 (29.3, 45.4)</b>
<b>Subsequent screen</b>						
BSWN	15	10,716	14.0(7.8, 23.1)	167	55,960	29.8 (25.5, 34.7)
BSCM	8	7,274	11.0(4.7, 21.7)	73	34,106	21.4 (16.8, 26.9)
BSAL	6	6,812	8.8(3.2, 19.2)	59	31,064	19.0 (14.5, 24.5)
BSM	9	7,577	11.9(5.4, 22.5)	167	53,147	31.4 (26.8, 36.6)
BSCtoC	3	8,029	3.7(0.8, 10.9)	118	50,876	23.2 (19.2, 27.8)
BSC	14	6,245	22.4(12.3, 37.6)	80	36,610	21.9 (17.3, 27.2)
BSSL	31	14,823	20.9(14.2, 29.7)	266	75,415	35.3 (31.2, 39.8)
BSHC/BSOS	3	4,004	7.5(1.5, 21.9)	80	28,037	28.5 (22.6, 35.5)
<b>Total</b>	<b>89</b>	<b>65,480</b>	<b>13.6(10.9, 16.7)</b>	<b>1,010</b>	<b>365,215</b>	<b>27.7 (26.0, 29.4)</b>

Target values for women aged 50–69 years are  $\geq 30.5$  per 10,000 screens for initial screens and  $\geq 17.3$  per 10,000 screens for subsequent screens.

### 3d Nodal involvement

**Description:** The proportion of women with invasive screen detected breast cancer that do not have nodal involvement. Note: this is calculated as 1 minus the proportion of women with invasive screen detected breast cancer who have nodal involvement.

#### Target for women aged 50–69 years:

Initial (prevalent) round: >70%


Subsequent (incident) round: >75%

**Table 3d.a: Invasive cancers without nodal involvement, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**


Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement	
<b>45–49 years</b>							
<b>Initial screens</b>							
BSWN	17	19	89.5 (66.9, 98.7)	53	73	72.6(60.9, 82.4)	1.23(1.00, 1.52)
BSCM	7	13	53.8 (25.1, 80.8)	35	59	59.3(45.7, 71.9)	0.91(0.53, 1.57)
BSAL	4	6	66.7 (22.3, 95.7)	26	39	66.7(49.8, 80.9)	1.00(0.54, 1.84)
BSM	15	22	68.2 (45.1, 86.1)	38	52	73.1(59.0, 84.4)	0.93(0.67, 1.30)
BSCtoC	13	21	61.9 (38.4, 81.9)	30	41	73.2(57.1, 85.8)	0.85(0.58, 1.24)
BSC	3	6	50.0 (11.8, 88.2)	39	56	69.6(55.9, 81.2)	0.72(0.32, 1.63)
BSSL	8	12	66.7 (34.9, 90.1)	43	60	71.7(58.6, 82.5)	0.93(0.60, 1.43)
BSHC/BSOS	0	0	-	24	33	72.7(54.5, 86.7)	-
<b>Total</b>	<b>67</b>	<b>99</b>	<b>67.7 (57.5, 76.7)</b>	<b>288</b>	<b>413</b>	<b>69.7(65.1, 74.1)</b>	<b>0.97(0.84, 1.13)</b>
<b>Subsequent screens</b>							
BSWN	8	13	61.5 (31.6, 86.1)	37	56	66.1(52.2, 78.2)	0.93(0.58, 1.49)
BSCM	6	9	66.7 (29.9, 92.5)	20	27	74.1(53.7, 88.9)	0.90(0.54, 1.50)
BSAL	4	5	80.0 (28.4, 99.5)	26	34	76.5(58.8, 89.3)	1.05(0.65, 1.68)
BSM	3	7	42.9 (9.9, 81.6)	27	41	65.9(49.4, 79.9)	0.65(0.27, 1.57)
BSCtoC	4	6	66.7 (22.3, 95.7)	17	26	65.4(44.3, 82.8)	1.02(0.54, 1.92)
BSC	5	6	83.3 (35.9, 99.6)	21	37	56.8(39.5, 72.9)	1.47(0.93, 2.31)
BSSL	10	13	76.9 (46.2, 95.0)	66	86	76.7(66.4, 85.2)	1.00(0.73, 1.38)
BSHC/BSOS	2	3	66.7 (9.4, 99.2)	13	21	61.9(38.4, 81.9)	1.08(0.45, 2.56)
<b>Total</b>	<b>42</b>	<b>62</b>	<b>67.7 (54.7, 79.1)</b>	<b>227</b>	<b>328</b>	<b>69.2(63.9, 74.2)</b>	<b>0.98(0.81, 1.18)</b>
<b>50–69 years</b>							
<b>Initial screens</b>							
BSWN	16	19	84.2 (60.4, 96.6)	60	75	80.0(69.2, 88.4)	1.05(0.84, 1.32)
BSCM	13	17	76.5 (50.1, 93.2)	52	75	69.3(57.6, 79.5)	1.10(0.81, 1.49)
BSAL	3	5	60.0 (14.7, 94.7)	52	66	78.8(67.0, 87.9)	0.76(0.37, 1.57)
BSM	28	39	71.8 (55.1, 85.0)	47	64	73.4(60.9, 83.7)	0.98(0.76, 1.25)
BSCtoC	18	25	72.0 (50.6, 87.9)	28	46	60.9(45.4, 74.9)	1.18(0.84, 1.66)
BSC	10	12	83.3 (51.6, 97.9)	34	57	59.6(45.8, 72.4)	1.40(1.00, 1.95)
BSSL	1	1	100.0 (2.5, 100.0)	24	39	61.5(44.6, 76.6)	1.62(0.26, 1.86) #
BSHC/BSOS	2	2	100.0 (15.8, 100.0)	12	20	60.0(36.1, 80.9)	1.67(0.48, 2.22) #
<b>Total</b>	<b>91</b>	<b>120</b>	<b>75.8 (67.2, 83.2)</b>	<b>309</b>	<b>442</b>	<b>69.9(65.4, 74.2)</b>	<b>1.08(0.96, 1.22)</b>
<b>Subsequent screens</b>							
BSWN	60	78	76.9 (66.0, 85.7)	401	508	78.9(75.1, 82.4)	0.97(0.86, 1.11)
BSCM	60	80	75.0 (64.1, 84.0)	196	267	73.4(67.7, 78.6)	1.02(0.88, 1.18)
BSAL	12	17	70.6 (44.0, 89.7)	168	219	76.7(70.5, 82.1)	0.92(0.67, 1.26)
BSM	90	124	72.6 (63.8, 80.2)	358	461	77.7(73.6, 81.4)	0.93(0.83, 1.05)
BSCtoC	64	76	84.2 (74.0, 91.6)	305	395	77.2(72.8, 81.3)	1.09(0.98, 1.22)
BSC	29	38	76.3 (59.8, 88.6)	240	320	75.0(69.9, 79.6)	1.02(0.84, 1.23)
BSSL	34	42	81.0 (65.9, 91.4)	587	723	81.2(78.1, 84.0)	1.00(0.86, 1.16)
BSHC/BSOS	9	11	81.8 (48.2, 97.7)	205	259	79.2(73.7, 83.9)	1.03(0.78, 1.38)
<b>Total</b>	<b>358</b>	<b>466</b>	<b>76.8 (72.7, 80.6)</b>	<b>2,460</b>	<b>3,152</b>	<b>78.0(76.6, 79.5)</b>	<b>0.98(0.93, 1.04)</b>

Ratios below one are unfavourable to Māori. Target values are >70% for initial screens and >75% for subsequent screens.

**Figure 3d.a Trends in the proportion of invasive breast cancers with no nodal involvement detected from an initial screen, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Figure 3d.b Trends in the proportion of invasive breast cancers with no nodal involvement detected from a subsequent screen, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Table 3d.b: Invasive cancers without nodal involvement, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement	
<b>45–49 years</b>							
<b>Initial screens</b>							
BSWN	1	3	33.3(0.8, 90.6)	52	70	74.3(62.4, 84.0)	0.45(0.09, 2.24)
BSCM	7	19	36.8(16.3, 61.6)	28	40	70.0(53.5, 83.4)	0.53(0.28, 0.98)
BSAL	2	5	40.0(5.3, 85.3)	24	34	70.6(52.5, 84.9)	0.57(0.19, 1.69)
BSM	1	2	50.0(1.3, 98.7)	37	50	74.0(59.7, 85.4)	0.68(0.17, 2.73)
BSCtoC	1	1	100.0(2.5, 100.0)	29	40	72.5(56.1, 85.4)	1.38(0.22, 1.52) #
BSC	3	6	50.0(11.8, 88.2)	36	50	72.0(57.5, 83.8)	0.69(0.31, 1.57)
BSSL	0	0	-	43	60	71.7(58.6, 82.5)	-
BSHC/BSOS	0	0	-	24	33	72.7(54.5, 86.7)	-
<b>Total</b>	<b>15</b>	<b>36</b>	<b>41.7(25.5, 59.2)</b>	<b>273</b>	<b>377</b>	<b>72.4(67.6, 76.9)</b>	<b>0.58(0.39, 0.85)</b>
<b>Subsequent screens</b>							
BSWN	1	1	100.0(2.5, 100.0)	36	55	65.5(51.4, 77.8)	1.53(0.24, 1.67) #
BSCM	3	3	100.0(29.2, 100.0)	17	24	70.8(48.9, 87.4)	1.41(0.56, 1.75) #
BSAL	3	3	100.0(29.2, 100.0)	23	31	74.2(55.4, 88.1)	1.35(0.54, 1.58) #
BSM	0	1	0.0(0.0, 97.5)	27	40	67.5(50.9, 81.4)	0.00(0.00, 5.86)
BSCtoC	0	0	-	17	26	65.4(44.3, 82.8)	-
BSC	0	0	-	21	37	56.8(39.5, 72.9)	-
BSSL	0	1	0.0(0.0, 97.5)	66	85	77.6(67.3, 86.0)	0.00(0.00, 4.89)
BSHC/BSOS	1	1	100.0(2.5, 100.0)	12	20	60.0(36.1, 80.9)	1.67(0.26, 2.13) #
<b>Total</b>	<b>8</b>	<b>10</b>	<b>80.0(44.4, 97.5)</b>	<b>219</b>	<b>318</b>	<b>68.9(63.5, 73.9)</b>	<b>1.16(0.84, 1.60)</b>
<b>50–69 years</b>							
<b>Initial screens</b>							
BSWN	2	6	33.3(4.3, 77.7)	58	69	84.1(73.3, 91.8)	0.40(0.13, 1.24)
BSCM	12	18	66.7(41.0, 86.7)	40	57	70.2(56.6, 81.6)	0.95(0.66, 1.37)
BSAL	8	11	72.7(39.0, 94.0)	44	55	80.0(67.0, 89.6)	0.91(0.62, 1.34)
BSM	0	0	-	47	64	73.4(60.9, 83.7)	-
BSCtoC	1	3	33.3(0.8, 90.6)	27	43	62.8(46.7, 77.0)	0.53(0.11, 2.67)
BSC	4	6	66.7(22.3, 95.7)	30	51	58.8(44.2, 72.4)	1.13(0.62, 2.09)
BSSL	0	0	-	24	39	61.5(44.6, 76.6)	-
BSHC/BSOS	0	1	0.0(0.0, 97.5)	12	19	63.2(38.4, 83.7)	0.00(0.00, 6.84)
<b>Total</b>	<b>27</b>	<b>45</b>	<b>60.0(44.3, 74.3)</b>	<b>282</b>	<b>397</b>	<b>71.0(66.3, 75.4)</b>	<b>0.84(0.66, 1.08)</b>
<b>Subsequent screens</b>							
BSWN	19	24	79.2(57.8, 92.9)	382	484	78.9(75.0, 82.5)	1.00(0.81, 1.24)
BSCM	24	38	63.2(46.0, 78.2)	172	229	75.1(69.0, 80.6)	0.84(0.65, 1.08)
BSAL	18	26	69.2(48.2, 85.7)	150	193	77.7(71.2, 83.4)	0.89(0.68, 1.16)
BSM	9	11	81.8(48.2, 97.7)	349	450	77.6(73.4, 81.3)	1.05(0.79, 1.40)
BSCtoC	2	2	100.0(15.8, 100.0)	303	393	77.1(72.6, 81.2)	1.30(0.38, 1.31) #
BSC	7	12	58.3(27.7, 84.8)	233	308	75.6(70.5, 80.3)	0.77(0.48, 1.25)
BSSL	7	7	100.0(59.0, 100.0)	580	716	81.0(77.9, 83.8)	1.23(0.78, 1.25) #
BSHC/BSOS	1	1	100.0(2.5, 100.0)	204	258	79.1(73.6, 83.9)	1.26(0.20, 1.27) #
<b>Total</b>	<b>87</b>	<b>121</b>	<b>71.9(63.0, 79.7)</b>	<b>2,373</b>	<b>3,031</b>	<b>78.3(76.8, 79.7)</b>	<b>0.92(0.82, 1.03)</b>


Ratios below one are unfavourable to Pacific women. Target values are >70% for initial screens and >75% for subsequent screens..

Table 3d.c: Invasive cancers without nodal involvement, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years


Lead provider	45–49 years			50–69 years		
	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement	Women with invasive cancers with no nodal involvement	Total invasive cancers	% of invasive cancers with no nodal involvement
<b>Initial screens</b>						
BSWN	28	39	71.8(55.1, 85.0)	14	15	93.3 (68.1, 99.8)
BSCM	15	25	60.0(38.7, 78.9)	15	26	57.7 (36.9, 76.6)
BSAL	13	17	76.5(50.1, 93.2)	16	24	66.7 (44.7, 84.4)
BSM	18	30	60.0(40.6, 77.3)	30	43	69.8 (53.9, 82.8)
BSCtoC	19	28	67.9(47.6, 84.1)	16	22	72.7 (49.8, 89.3)
BSC	14	22	63.6(40.7, 82.8)	12	19	63.2 (38.4, 83.7)
BSSL	26	34	76.5(58.8, 89.3)	6	11	54.5 (23.4, 83.3)
BSHC/BSOS	14	19	73.7(48.8, 90.9)	5	11	45.5 (16.7, 76.6)
<b>Total</b>	<b>147</b>	<b>214</b>	<b>68.7(62.0, 74.8)</b>	<b>114</b>	<b>171</b>	<b>66.7 (59.1, 73.7)</b>
<b>Subsequent screens</b>						
BSWN	16	26	61.5(40.6, 79.8)	207	262	79.0 (73.6, 83.8)
BSCM	17	21	81.0(58.1, 94.6)	107	145	73.8 (65.8, 80.7)
BSAL	9	14	64.3(35.1, 87.2)	77	106	72.6 (63.1, 80.9)
BSM	11	16	68.8(41.3, 89.0)	201	276	72.8 (67.2, 78.0)
BSCtoC	10	14	71.4(41.9, 91.6)	155	199	77.9 (71.5, 83.5)
BSC	15	21	71.4(47.8, 88.7)	104	139	74.8 (66.8, 81.8)
BSSL	37	49	75.5(61.1, 86.7)	299	364	82.1 (77.8, 85.9)
BSHC/BSOS	4	5	80.0(28.4, 99.5)	100	123	81.3 (73.3, 87.8)
<b>Total</b>	<b>119</b>	<b>166</b>	<b>71.7(64.2, 78.4)</b>	<b>1,250</b>	<b>1,614</b>	<b>77.4 (75.3, 79.5)</b>

Target values are >70% for initial screens and >75% for subsequent screens.

**Figure 3d.c Trends in the proportion of invasive breast cancers with no nodal involvement detected from an initial screen, total women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Figure 3d.d Trends in the proportion of invasive breast cancers with no nodal involvement detected from a subsequent screen, total women aged 50–69 years, by Lead Provider, July 2008 to June 2014**



### 3e Ductal carcinoma in situ

#### Description:

The percentage of all women with screen detected cancer who are diagnosed as having Ductal Carcinoma in Situ (DCIS) as their primary lesion.

#### Target for women aged 50–69 years:

10%-25% of all cancers detected by the programme are DCIS.

**Table 3e.a: Women with DCIS as a percentage of all screen detected cancers, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	Number of DCIS	Total number of cancers	% of total cancer that are DCIS (95% CI)	Number of DCIS	Total number of cancers	% of total cancers that are DCIS (95% CI)	
<b>45–49 years</b>							
BSWN	5	38	13.2 (4.4, 28.1)	55	189	29.1 (22.7, 36.1)	0.45(0.19, 1.05)
BSCM	7	29	24.1 (10.3, 43.5)	22	109	20.2 (13.1, 28.9)	1.20(0.57, 2.52)
BSAL	3	16	18.8 (4.0, 45.6)	33	111	29.7 (21.4, 39.1)	0.63(0.22, 1.82)
BSM	8	37	21.6 (9.8, 38.2)	31	124	25.0 (17.7, 33.6)	0.86(0.44, 1.72)
BSCtoC	4	31	12.9 (3.6, 29.8)	30	97	30.9 (21.9, 41.1)	0.42(0.16, 1.09)
BSC	1	13	7.7 (0.2, 36.0)	38	131	29.0 (21.4, 37.6)	0.27(0.04, 1.78)
BSSL	5	30	16.7 (5.6, 34.7)	65	212	30.7 (24.5, 37.3)	0.54(0.24, 1.24)
BSHC/BSOS	4	7	57.1 (18.4, 90.1)	22	78	28.2 (18.6, 39.5)	2.03(0.97, 4.22)
<b>Total</b>	<b>37</b>	<b>201</b>	<b>18.4 (13.3, 24.5)</b>	<b>296</b>	<b>1,051</b>	<b>28.2 (25.5, 31.0)</b>	<b>0.65(0.48, 0.89)</b>
<b>50–69 years</b>							
BSWN	25	128	19.5 (13.1, 27.5)	186	778	23.9 (20.9, 27.1)	0.82(0.56, 1.19)
BSCM	10	107	9.3 (4.6, 16.5)	111	459	24.2 (20.3, 28.4)	0.39(0.21, 0.71)
BSAL	6	32	18.8 (7.2, 36.4)	109	424	25.7 (21.6, 30.1)	0.73(0.35, 1.53)
BSM	24	191	12.6 (8.2, 18.1)	142	670	21.2 (18.2, 24.5)	0.59(0.40, 0.89)
BSCtoC	13	114	11.4 (6.2, 18.7)	81	523	15.5 (12.5, 18.9)	0.74(0.43, 1.28)
BSC	14	64	21.9 (12.5, 34.0)	112	492	22.8 (19.1, 26.7)	0.96(0.59, 1.57)
BSSL	10	54	18.5 (9.3, 31.4)	199	963	20.7 (18.1, 23.4)	0.90(0.51, 1.59)
BSHC/BSOS	3	17	17.6 (3.8, 43.4)	66	350	18.9 (14.9, 23.4)	0.94(0.33, 2.67)
<b>Total</b>	<b>105</b>	<b>707</b>	<b>14.9 (12.3, 17.7)</b>	<b>1,006</b>	<b>4,659</b>	<b>21.6 (20.4, 22.8)</b>	<b>0.69(0.57, 0.83)</b>

Ratios below 1 show Māori women had a lower proportion of screen-detected cancers that were DCIS than non-Māori women. Ratios in italics show a statistically significant difference between Māori and non-Māori.

**Table 3e.b: Women with DCIS as a percentage of all screen detected cancers, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	Number of DCIS	Total number of cancers	% of total cancer that are DCIS (95% CI)	Number of DCIS	Total number of cancers	% of total cancers that are DCIS (95% CI)	
<b>45–49 years</b>							
BSWN	3	9	33.3 (7.5, 70.1)	52	180	28.9 (22.4, 36.1)	1.15(0.45, 2.99)
BSCM	3	26	11.5 (2.4, 30.2)	19	83	22.9 (14.4, 33.4)	0.50(0.16, 1.57)
BSAL	1	10	10.0 (0.3, 44.5)	32	101	31.7 (22.8, 41.7)	0.32(0.05, 2.07)
BSM	0	3	0.0 (0.0, 70.8)	31	121	25.6 (18.1, 34.4)	0.00(0.00, 5.10)
BSCtoC	0	1	0.0 (0.0, 97.5)	30	96	31.2 (22.2, 41.5)	0.00(0.00, 12.56)
BSC	3	9	33.3 (7.5, 70.1)	35	122	28.7 (20.9, 37.6)	1.16(0.44, 3.05)
BSSL	1	3	33.3 (0.8, 90.6)	64	209	30.6 (24.4, 37.4)	1.09(0.22, 5.46)
BSHC/BSOS	0	1	0.0 (0.0, 97.5)	22	77	28.6 (18.8, 40.0)	0.00(0.00, 14.06)
<b>Total</b>	<b>11</b>	<b>62</b>	<b>17.7 (9.2, 29.5)</b>	<b>285</b>	<b>989</b>	<b>28.8 (26.0, 31.8)</b>	<b>0.62(0.36, 1.06)</b>
<b>50–69 years</b>							
BSWN	12	44	27.3 (15.0, 42.8)	174	734	23.7 (20.7, 27.0)	1.15(0.70, 1.90)
BSCM	18	75	24.0 (14.9, 35.3)	93	384	24.2 (20.0, 28.8)	0.99(0.64, 1.54)
BSAL	7	51	13.7 (5.7, 26.3)	102	373	27.3 (22.9, 32.2)	0.50(0.25, 1.02)
BSM	2	13	15.4 (1.9, 45.4)	140	657	21.3 (18.2, 24.6)	0.72(0.20, 2.61)
BSCtoC	1	6	16.7 (0.4, 64.1)	80	517	15.5 (12.5, 18.9)	1.08(0.18, 6.52)
BSC	6	24	25.0 (9.8, 46.7)	106	468	22.6 (18.9, 26.7)	1.10(0.54, 2.25)
BSSL	0	7	0.0 (0.0, 41.0)	199	956	20.8 (18.3, 23.5)	0.00(0.00, 2.56)
BSHC/BSOS	1	3	33.3 (0.8, 90.6)	65	347	18.7 (14.8, 23.2)	1.78(0.35, 8.95)
<b>Total</b>	<b>47</b>	<b>223</b>	<b>21.1 (15.9, 27.0)</b>	<b>959</b>	<b>4,436</b>	<b>21.6 (20.4, 22.9)</b>	<b>0.97(0.75, 1.26)</b>


Ratios below 1 show Pacific women had a lower proportion of screen-detected cancers that were DCIS than non-Māori non-Pacific women..

**Table 3e.c: Women with DCIS as a percentage of all screen detected cancers, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**


Lead provider	45–49 years			50–69 years		
	Number of DCIS	Total number of cancers	% of total cancer that are DCIS (95% CI)	Number of DCIS	Total number of cancers	% of total cancers that are DCIS (95% CI)
BSWN	20	86	23.3 (14.8, 33.6)	97	378	25.7 (21.3, 30.4)
BSCM	7	54	13.0 (5.4, 24.9)	44	218	20.2 (15.1, 26.1)
BSAL	15	49	30.6 (18.3, 45.4)	39	180	21.7 (15.9, 28.4)
BSM	16	62	25.8 (15.5, 38.5)	79	402	19.7 (15.9, 23.9)
BSCtoC	12	54	22.2 (12.0, 35.6)	41	262	15.6 (11.5, 20.6)
BSC	11	54	20.4 (10.6, 33.5)	49	208	23.6 (18.0, 29.9)
BSSL	34	118	28.8 (20.8, 37.9)	108	484	22.3 (18.7, 26.3)
BSHC/BSOS	15	41	36.6 (22.1, 53.1)	29	164	17.7 (12.2, 24.4)
<b>Total</b>	<b>130</b>	<b>518</b>	<b>25.1 (21.4, 29.1)</b>	<b>486</b>	<b>2,296</b>	<b>21.2 (19.5, 22.9)</b>

Target values between 10% and 25% for women aged 50–69 years.

Figure 3e.a Trends in the proportion of detected breast cancer that are DCIS, Māori and non-Māori aged 50–69 years by Lead Provider, July 2008 to June 2014



**Figure 3e.b Trends in the proportion of detected breast cancer that are DCIS, total women aged 50–69 years by Lead Provider, July 2008 to June 2014**



## SECTION 4: TREATMENT

### 4a Proportion of invasive cancers having a surgical axillary procedure

#### Description:

Percentage of all women who are operated on for a screen detected invasive cancer, over 1mm in size, who have a surgical axillary procedure.

#### Target:

95% of women operated on for invasive cancer over 1mm in size, should normally have a surgical axillary procedure.

**Table 4a.a: Percentage of invasive cancers having a surgical axillary procedure, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure	
<b>45–49 years</b>							
BSWN	32	32	100.0(89.1, 100.0)	124	125	99.2(95.6, 100.0)	1.01(0.91, 1.03) #
BSCM	22	22	100.0(84.6, 100.0)	82	83	98.8(93.5, 100.0)	1.01(0.87, 1.05) #
BSAL	10	11	90.9(58.7, 99.8)	72	72	100.0(95.0, 100.0)	0.91(0.62, 1.00) #
BSM	29	29	100.0(88.1, 100.0)	92	92	100.0(96.1, 100.0)	1.00(0.89, 1.02) #
BSCtoC	25	26	96.2(80.4, 99.9)	65	65	100.0(94.5, 100.0)	0.96(0.82, 1.02) #
BSC	12	12	100.0(73.5, 100.0)	92	92	100.0(96.1, 100.0)	1.00(0.76, 1.02) #
BSSL	25	25	100.0(86.3, 100.0)	145	145	100.0(97.5, 100.0)	1.00(0.87, 1.01) #
BSHC/BSOS	3	3	100.0(29.2, 100.0)	53	53	100.0(93.3, 100.0)	1.00(0.40, 1.02) #
<b>Total</b>	<b>158</b>	<b>160</b>	<b>98.8(95.6, 99.8)</b>	<b>725</b>	<b>727</b>	<b>99.7(99.0, 100.0)</b>	<b>0.99(0.97, 1.01)</b>
<b>50–69 years</b>							
BSWN	94	97	96.9(91.2, 99.4)	561	577	97.2(95.5, 98.4)	1.00(0.96, 1.04)
BSCM	93	96	96.9(91.1, 99.4)	331	336	98.5(96.6, 99.5)	0.98(0.95, 1.02)
BSAL	22	22	100.0(84.6, 100.0)	282	284	99.3(97.5, 99.9)	1.01(0.86, 1.01) #
BSM	158	160	98.8(95.6, 99.8)	511	518	98.6(97.2, 99.5)	1.00(0.98, 1.02)
BSCtoC	96	97	99.0(94.4, 100.0)	428	429	99.8(98.7, 100.0)	0.99(0.97, 1.01)
BSC	49	50	98.0(89.4, 99.9)	363	372	97.6(95.5, 98.9)	1.00(0.96, 1.05)
BSSL	43	43	100.0(91.8, 100.0)	743	756	98.3(97.1, 99.1)	1.02(0.94, 1.02) #
BSHC/BSOS	13	13	100.0(75.3, 100.0)	273	275	99.3(97.4, 99.9)	1.01(0.78, 1.01) #
<b>Total</b>	<b>568</b>	<b>578</b>	<b>98.3(96.8, 99.2)</b>	<b>3,492</b>	<b>3,547</b>	<b>98.4(98.0, 98.8)</b>	<b>1.00(0.99, 1.01)</b>

Ratios below one are unfavourable to Māori.

**Table 4a.b: Percentage of invasive cancers having a surgical axillary procedure, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure	
<b>45–49 years</b>							
BSWN	4	4	100.0(39.8, 100.0)	120	121	99.2(95.5, 100.0)	1.01(0.49, 1.01) #
BSCM	22	22	100.0(84.6, 100.0)	60	61	98.4(91.2, 100.0)	1.02(0.88, 1.07) #
BSAL	8	8	100.0(63.1, 100.0)	64	64	100.0(94.4, 100.0)	1.00(0.67, 1.02) #
BSM	3	3	100.0(29.2, 100.0)	89	89	100.0(95.9, 100.0)	1.00(0.40, 1.01) #
BSCtoC	1	1	100.0(2.5, 100.0)	64	64	100.0(94.4, 100.0)	1.00(0.16, 1.00) #
BSC	6	6	100.0(54.1, 100.0)	86	86	100.0(95.8, 100.0)	1.00(0.60, 1.01) #
BSSL	1	1	100.0(2.5, 100.0)	144	144	100.0(97.5, 100.0)	1.00(0.16, 0.99) #
BSHC/BSOS	1	1	100.0(2.5, 100.0)	52	52	100.0(93.2, 100.0)	1.00(0.16, 1.01) #
<b>Total</b>	<b>46</b>	<b>46</b>	<b>100.0(92.3, 100.0)</b>	<b>679</b>	<b>681</b>	<b>99.7(98.9, 100.0)</b>	<b>1.00(0.93, 1.01) #</b>
<b>50–69 years</b>							
BSWN	28	30	93.3(77.9, 99.2)	533	547	97.4(95.7, 98.6)	0.96(0.87, 1.05)
BSCM	54	54	100.0(93.4, 100.0)	277	282	98.2(95.9, 99.4)	1.02(0.95, 1.03) #
BSAL	37	37	100.0(90.5, 100.0)	245	247	99.2(97.1, 99.9)	1.01(0.92, 1.02) #
BSM	11	11	100.0(71.5, 100.0)	500	507	98.6(97.2, 99.4)	1.01(0.75, 1.02) #
BSCtoC	5	5	100.0(47.8, 100.0)	423	424	99.8(98.7, 100.0)	1.00(0.54, 1.00) #
BSC	16	16	100.0(79.4, 100.0)	347	356	97.5(95.3, 98.8)	1.03(0.83, 1.03) #
BSSL	7	7	100.0(59.0, 100.0)	736	749	98.3(97.1, 99.1)	1.02(0.64, 1.02) #
BSHC/BSOS	2	2	100.0(15.8, 100.0)	271	273	99.3(97.4, 99.9)	1.01(0.29, 1.00) #
<b>Total</b>	<b>160</b>	<b>162</b>	<b>98.8(95.6, 99.9)</b>	<b>3,332</b>	<b>3,385</b>	<b>98.4(98.0, 98.8)</b>	<b>1.00(0.99, 1.02)</b>

Ratios below one are unfavourable to Māori. Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women

**Table 4a.c: Percentage of invasive cancers having a surgical axillary procedure, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure	Number having a surgical axillary procedure for invasive cancers >1mm	Number having an operation for invasive cancers >1mm	% of invasive cancers, >1mm, having a surgical axillary procedure
BSWN	62	63	98.4(91.5, 100.0)	266	274	97.1(94.3, 98.7)
BSCM	44	44	100.0(92.0, 100.0)	162	166	97.6(93.9, 99.3)
BSAL	30	30	100.0(88.4, 100.0)	129	130	99.2(95.8, 100.0)
BSM	45	45	100.0(92.1, 100.0)	309	315	98.1(95.9, 99.3)
BSCtoC	41	42	97.6(87.4, 99.9)	211	213	99.1(96.6, 99.9)
BSC	43	43	100.0(91.8, 100.0)	151	157	96.2(91.9, 98.6)
BSSL	83	83	100.0(95.7, 100.0)	365	371	98.4(96.5, 99.4)
BSHC/BSOS	23	23	100.0(85.2, 100.0)	130	132	98.5(94.6, 99.8)
<b>Total</b>	<b>371</b>	<b>373</b>	<b>99.5(98.1, 99.9)</b>	<b>1,723</b>	<b>1,758</b>	<b>98.0(97.2, 98.6)</b>

## 4b Proportion of invasive cancers having a single excisional procedure

### Description:


The proportion of women with invasive cancer who have a single excisional breast treatment procedure.

**Target:** No target.

**Table 4b.a: Proportion of invasive cancers having a single excisional breast treatment procedure, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)	
<b>45–49 years</b>							
BSWN	28	33	84.8(68.1, 94.9)	109	131	83.2(75.7, 89.2)	1.02(0.87, 1.20)
BSCM	20	22	90.9(70.8, 98.9)	75	85	88.2(79.4, 94.2)	1.03(0.88, 1.20)
BSAL	11	12	91.7(61.5, 99.8)	71	77	92.2(83.8, 97.1)	0.99(0.83, 1.19)
BSM	22	29	75.9(56.5, 89.7)	77	93	82.8(73.6, 89.8)	0.92(0.73, 1.15)
BSCtoC	21	27	77.8(57.7, 91.4)	54	67	80.6(69.1, 89.2)	0.97(0.76, 1.22)
BSC	11	12	91.7(61.5, 99.8)	77	93	82.8(73.6, 89.8)	1.11(0.91, 1.34)
BSSL	20	25	80.0(59.3, 93.2)	123	146	84.2(77.3, 89.7)	0.95(0.77, 1.17)
BSHC/BSOS	3	3	100.0(29.2, 100.0)	48	55	87.3(75.5, 94.7)	1.15(0.46, 1.22) #
<b>Total</b>	<b>136</b>	<b>163</b>	<b>83.4(76.8, 88.8)</b>	<b>634</b>	<b>747</b>	<b>84.9(82.1, 87.4)</b>	<b>0.98(0.91, 1.06)</b>
<b>50–69 years</b>							
BSWN	86	100	86.0(77.6, 92.1)	508	583	87.1(84.1, 89.7)	0.99(0.91, 1.07)
BSCM	90	96	93.8(86.9, 97.7)	315	343	91.8(88.4, 94.5)	1.02(0.96, 1.08)
BSAL	21	24	87.5(67.6, 97.3)	261	305	85.6(81.1, 89.3)	1.02(0.87, 1.20)
BSM	143	165	86.7(80.5, 91.5)	446	525	85.0(81.6, 87.9)	1.02(0.95, 1.09)
BSCtoC	76	99	76.8(67.2, 84.7)	356	441	80.7(76.7, 84.3)	0.95(0.85, 1.07)
BSC	46	50	92.0(80.8, 97.8)	321	376	85.4(81.4, 88.8)	1.08(0.98, 1.18)
BSSL	33	43	76.7(61.4, 88.2)	662	761	87.0(84.4, 89.3)	0.88(0.75, 1.04)
BSHC/BSOS	12	13	92.3(64.0, 99.8)	234	283	82.7(77.8, 86.9)	1.12(0.95, 1.32)
<b>Total</b>	<b>507</b>	<b>590</b>	<b>85.9(82.9, 88.6)</b>	<b>3,103</b>	<b>3,617</b>	<b>85.8(84.6, 86.9)</b>	<b>1.00(0.97, 1.04)</b>

**Figure 4b.a: Trends in the proportion of invasive cancers having a single excisional procedure, Māori and non-Māori women aged 50–69 years by Lead Provider, July 2008 to June 2014**



**Table 4b.b: Proportion of invasive cancers having a single excisional breast treatment procedure, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**


Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)	
<b>45–49 years</b>							
BSWN	5	5	100.0(47.8, 100.0)	104	126	82.5(74.8, 88.7)	1.21(0.66, 1.27) #
BSCM	22	22	100.0(84.6, 100.0)	53	63	84.1(72.7, 92.1)	1.19(1.00, 1.33) #
BSAL	7	8	87.5(47.3, 99.7)	64	69	92.8(83.9, 97.6)	0.94(0.72, 1.24)
BSM	3	3	100.0(29.2, 100.0)	74	90	82.2(72.7, 89.5)	1.22(0.48, 1.28) #
BSCtoC	1	1	100.0(2.5, 100.0)	53	66	80.3(68.7, 89.1)	1.25(0.20, 1.30) #
BSC	5	6	83.3(35.9, 99.6)	72	87	82.8(73.2, 90.0)	1.01(0.70, 1.46)
BSSL	1	1	100.0(2.5, 100.0)	122	145	84.1(77.2, 89.7)	1.19(0.19, 1.20) #
BSHC/BSOS	1	1	100.0(2.5, 100.0)	47	54	87.0(75.1, 94.6)	1.15(0.18, 1.19) #
<b>Total</b>	<b>45</b>	<b>47</b>	<b>95.7(85.5, 99.5)</b>	<b>589</b>	<b>700</b>	<b>84.1(81.2, 86.8)</b>	<b>1.14(1.06, 1.22)</b>
<b>50–69 years</b>							
BSWN	28	30	93.3(77.9, 99.2)	480	553	86.8(83.7, 89.5)	1.08(0.97, 1.19)
BSCM	52	55	94.5(84.9, 98.9)	263	288	91.3(87.5, 94.3)	1.04(0.96, 1.11)
BSAL	32	39	82.1(66.5, 92.5)	229	266	86.1(81.3, 90.0)	0.95(0.82, 1.11)
BSM	10	11	90.9(58.7, 99.8)	436	514	84.8(81.4, 87.8)	1.07(0.89, 1.30)
BSCtoC	5	5	100.0(47.8, 100.0)	351	436	80.5(76.5, 84.1)	1.24(0.67, 1.26) #
BSC	12	16	75.0(47.6, 92.7)	309	360	85.8(81.8, 89.3)	0.87(0.66, 1.16)
BSSL	6	7	85.7(42.1, 99.6)	656	754	87.0(84.4, 89.3)	0.99(0.73, 1.33)
BSHC/BSOS	2	2	100.0(15.8, 100.0)	232	281	82.6(77.6, 86.8)	1.21(0.36, 1.22) #
<b>Total</b>	<b>147</b>	<b>165</b>	<b>89.1(83.3, 93.4)</b>	<b>2,956</b>	<b>3,452</b>	<b>85.6(84.4, 86.8)</b>	<b>1.04(0.98, 1.10)</b>

Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women.

**Table 4b.c: Proportion of invasive cancers having a single excisional breast treatment procedure, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)	No. having a single excisional procedure for invasive cancer	No. of invasive cancers having surgical breast procedure	% of invasive cancers having a single excisional breast treatment procedure (95% CI)
BSWN	53	66	80.3(68.7, 89.1)	249	278	89.6(85.4, 92.9)
BSCM	41	46	89.1(76.4, 96.4)	153	170	90.0(84.5, 94.1)
BSAL	31	32	96.9(83.8, 99.9)	122	139	87.8(81.1, 92.7)
BSM	40	46	87.0(73.7, 95.1)	284	320	88.8(84.8, 92.0)
BSCtoC	33	42	78.6(63.2, 89.7)	167	220	75.9(69.7, 81.4)
BSC	36	43	83.7(69.3, 93.2)	138	157	87.9(81.7, 92.6)
BSSL	71	83	85.5(76.1, 92.3)	318	374	85.0(81.0, 88.5)
BSHC/BSOS	22	25	88.0(68.8, 97.5)	117	135	86.7(79.7, 91.9)
<b>Total</b>	<b>327</b>	<b>383</b>	<b>85.4(81.4, 88.8)</b>	<b>1,548</b>	<b>1,793</b>	<b>86.3(84.7, 87.9)</b>

**Figure 4b.b: Trends in the proportion of invasive cancers having a single excisional procedure, total women aged 50–69 years by Lead Provider, July 2008 to June 2014**



## 4c Proportion of DCIS where no axillary dissection was carried out

### Description:

The proportion of women who have surgery for DCIS who do not have an axillary dissection

### Target for women aged 50–69 years:

>95%

**Table 4c.a: Proportion of women with DCIS not having axillary dissection, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI) #
	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)	
<b>45–49 years</b>							
BSWN	4	4	100.0(39.8, 100.0)	42	42	100.0(91.6, 100.0)	1.00(0.49, 1.03) #
BSCM	5	5	100.0(47.8, 100.0)	12	12	100.0(73.5, 100.0)	1.00(0.58, 1.22) #
BSAL	2	2	100.0(15.8, 100.0)	23	23	100.0(85.2, 100.0)	1.00(0.30, 1.06) #
BSM	8	8	100.0(63.1, 100.0)	21	21	100.0(83.9, 100.0)	1.00(0.69, 1.12) #
BSCtoC	4	4	100.0(39.8, 100.0)	25	25	100.0(86.3, 100.0)	1.00(0.50, 1.07) #
BSC	0	0	-	28	28	100.0(87.7, 100.0)	-
BSSL	2	3	66.7(9.4, 99.2)	43	43	100.0(91.8, 100.0)	0.67(0.20, 0.96) #
BSHC/BSOS	3	3	100.0(29.2, 100.0)	17	17	100.0(80.5, 100.0)	1.00(0.42, 1.12) #
<b>Total</b>	<b>28</b>	<b>29</b>	<b>96.6(82.2, 99.9)</b>	<b>211</b>	<b>211</b>	<b>100.0(98.3, 100.0)</b>	<b>0.97(0.83, 1.00) #</b>
<b>50–69 years</b>							
BSWN	21	22	95.5(77.2, 99.9)	156	157	99.4(96.5, 100.0)	0.96(0.88, 1.05)
BSCM	7	7	100.0(59.0, 100.0)	99	99	100.0(96.3, 100.0)	1.00(0.64, 1.01) #
BSAL	5	5	100.0(47.8, 100.0)	87	88	98.9(93.8, 100.0)	1.01(0.55, 1.03) #
BSM	22	24	91.7(73.0, 99.0)	125	125	100.0(97.1, 100.0)	0.92(0.75, 0.98) #
BSCtoC	9	9	100.0(66.4, 100.0)	73	74	98.6(92.7, 100.0)	1.01(0.71, 1.04) #
BSC	13	13	100.0(75.3, 100.0)	87	87	100.0(95.8, 100.0)	1.00(0.78, 1.02) #
BSSL	9	9	100.0(66.4, 100.0)	171	173	98.8(95.9, 99.9)	1.01(0.70, 1.02) #
BSHC/BSOS	3	3	100.0(29.2, 100.0)	60	60	100.0(94.0, 100.0)	1.00(0.40, 1.01) #
<b>Total</b>	<b>89</b>	<b>92</b>	<b>96.7(90.8, 99.3)</b>	<b>858</b>	<b>863</b>	<b>99.4(98.7, 99.8)</b>	<b>0.97(0.94, 1.01)</b>

Ratios below one are unfavourable to Māori. This indicator excludes women who have had immediate reconstruction. Sentinel node biopsies and nodal sampling are not coded as axillary dissection.

**Table 4c.b: Proportion of women with DCIS not having axillary dissection, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)	
<b>45–49 years</b>							
BSWN	2	2	100.0(15.8, 100.0)	40	40	100.0(91.2, 100.0)	1.00(0.30, 1.02) #
BSCM	1	1	100.0(2.5, 100.0)	11	11	100.0(71.5, 100.0)	1.00(0.17, 1.16) #
BSAL	0	0	-	23	23	100.0(85.2, 100.0)	-
BSM	0	0	-	21	21	100.0(83.9, 100.0)	-
BSCtoC	0	0	-	25	25	100.0(86.3, 100.0)	-
BSC	3	3	100.0(29.2, 100.0)	25	25	100.0(86.3, 100.0)	1.00(0.41, 1.07) #
BSSL	1	1	100.0(2.5, 100.0)	42	42	100.0(91.6, 100.0)	1.00(0.16, 1.01) #
BSHC/BSOS	0	0	-	17	17	100.0(80.5, 100.0)	-
<b>Total</b>	<b>7</b>	<b>7</b>	<b>100.0(59.0, 100.0)</b>	<b>204</b>	<b>204</b>	<b>100.0(98.2, 100.0)</b>	<b>1.00(0.63, 1.00) #</b>
<b>50–69 years</b>							
BSWN	11	11	100.0(71.5, 100.0)	145	146	99.3(96.2, 100.0)	1.01(0.75, 1.02) #
BSCM	17	17	100.0(80.5, 100.0)	82	82	100.0(95.6, 100.0)	1.00(0.82, 1.02) #
BSAL	6	6	100.0(54.1, 100.0)	81	82	98.8(93.4, 100.0)	1.01(0.60, 1.03) #
BSM	2	2	100.0(15.8, 100.0)	123	123	100.0(97.0, 100.0)	1.00(0.29, 1.00) #
BSCtoC	1	1	100.0(2.5, 100.0)	72	73	98.6(92.6, 100.0)	1.01(0.16, 1.02) #
BSC	6	6	100.0(54.1, 100.0)	81	81	100.0(95.5, 100.0)	1.00(0.60, 1.01) #
BSSL	0	0	-	171	173	98.8(95.9, 99.9)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	59	59	100.0(93.9, 100.0)	1.00(0.16, 1.00) #
<b>Total</b>	<b>44</b>	<b>44</b>	<b>100.0(92.0, 100.0)</b>	<b>814</b>	<b>819</b>	<b>99.4(98.6, 99.8)</b>	<b>1.01(0.93, 1.01) #</b>

Ratios below one are unfavourable to Pacific women. This indicator excludes women who have had immediate reconstruction. Sentinel node biopsies and nodal sampling are not coded as axillary dissection.

**Table 4c.c: Proportion of women with DCIS not having axillary dissection, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)	Number having surgery for DCIS who do not have an axillary dissection	Number. having surgery for DCIS	% of DCIS women not having axillary dissection (95% CI)
BSWN	16	16	100.0(79.4, 100.0)	80	81	98.8(93.3, 100.0)
BSCM	6	6	100.0(54.1, 100.0)	40	40	100.0(91.2, 100.0)
BSAL	12	12	100.0(73.5, 100.0)	31	31	100.0(88.8, 100.0)
BSM	13	13	100.0(75.3, 100.0)	70	70	100.0(94.9, 100.0)
BSCtoC	9	9	100.0(66.4, 100.0)	35	35	100.0(90.0, 100.0)
BSC	7	7	100.0(59.0, 100.0)	40	40	100.0(91.2, 100.0)
BSSL	19	20	95.0(75.1, 99.9)	92	93	98.9(94.2, 100.0)
BSHC/BSOS	12	12	100.0(73.5, 100.0)	27	27	100.0(87.2, 100.0)
<b>Total</b>	<b>94</b>	<b>95</b>	<b>98.9(94.3, 100.0)</b>	<b>415</b>	<b>417</b>	<b>99.5(98.3, 99.9)</b>

This indicator excludes women who have had immediate reconstruction. Sentinel node biopsies and nodal sampling are not coded as axillary dissection.

## 4e Proportion of DCIS having breast conserving surgery

### Definition:

The proportion of women diagnosed with sole DCIS of pathological diameter  $\leq 20$ mm who have breast conserving surgery (BCS).

### Target for women aged 50–69 years:

The majority ( $>50\%$ ) of screen-detected DCIS  $\leq 20$ mm are treated by BCS.

**Table 4e.a: Proportion of DCIS  $\leq 20$ mm having BCS, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of DCIS $\leq 20$ mm having BCS	No. of DCIS $\leq 20$ mm who are operated on	% of DCIS $\leq 20$ mm who have BCS (95% CI)	No. of DCIS $\leq 20$ mm having BCS	No. of DCIS $\leq 20$ mm who are operated on	% of DCIS $\leq 20$ mm who have BCS (95% CI)	
<b>45–49 years</b>							
BSWN	2	2	100.0(15.8, 100.0)	27	28	96.4(81.7, 99.9)	1.04(0.31, 1.11) #
BSCM	2	4	50.0(6.8, 93.2)	8	8	100.0(63.1, 100.0)	0.50(0.16, 1.01) #
BSAL	0	0	-	7	7	100.0(59.0, 100.0)	-
BSM	5	5	100.0(47.8, 100.0)	16	18	88.9(65.3, 98.6)	1.12(0.62, 1.37) #
BSCtoC	1	1	100.0(2.5, 100.0)	15	17	88.2(63.6, 98.5)	1.13(0.19, 1.30) #
BSC	0	0	-	21	24	87.5(67.6, 97.3)	-
BSSL	2	2	100.0(15.8, 100.0)	33	35	94.3(80.8, 99.3)	1.06(0.32, 1.12) #
BSHC/BSOS	0	1	0.0(0.0, 97.5)	8	11	72.7(39.0, 94.0)	0.00(0.00, 6.44)
<b>Total</b>	<b>12</b>	<b>15</b>	<b>80.0(51.9, 95.7)</b>	<b>135</b>	<b>148</b>	<b>91.2(85.4, 95.2)</b>	<b>0.88(0.68, 1.14)</b>
<b>50–69 years</b>							
BSWN	13	16	81.2(54.4, 96.0)	95	111	85.6(77.6, 91.5)	0.95(0.74, 1.22)
BSCM	3	3	100.0(29.2, 100.0)	45	57	78.9(66.1, 88.6)	1.27(0.51, 1.38) #
BSAL	1	1	100.0(2.5, 100.0)	31	34	91.2(76.3, 98.1)	1.10(0.18, 1.16) #
BSM	9	12	75.0(42.8, 94.5)	72	80	90.0(81.2, 95.6)	0.83(0.60, 1.16)
BSCtoC	3	6	50.0(11.8, 88.2)	34	48	70.8(55.9, 83.0)	0.71(0.31, 1.60)
BSC	3	3	100.0(29.2, 100.0)	56	67	83.6(72.5, 91.5)	1.20(0.48, 1.27) #
BSSL	4	5	80.0(28.4, 99.5)	99	107	92.5(85.8, 96.7)	0.86(0.56, 1.34)
BSHC/BSOS	1	1	100.0(2.5, 100.0)	33	43	76.7(61.4, 88.2)	1.30(0.21, 1.41) #
<b>Total</b>	<b>37</b>	<b>47</b>	<b>78.7(64.3, 89.3)</b>	<b>465</b>	<b>547</b>	<b>85.0(81.7, 87.9)</b>	<b>0.93(0.79, 1.08)</b>

Ratios below one are unfavourable to Māori. Target is  $>50\%$  for women 50–69 years.

**Table 4e.b: Proportion of DCIS ≤ 20mm having BCS, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of DCIS ≤20mm having BCS	No. of DCIS ≤ 20mm who are operated on	% of DCIS ≤20mm who have BCS (95% CI)	No. of DCIS ≤20mm having BCS	No. of DCIS ≤ 20mm who are operated on	% of DCIS ≤20mm who have BCS (95% CI)	
<b>45–49 years</b>							
BSWN	2	2	100.0(15.8, 100.0)	25	26	96.2(80.4, 99.9)	1.04(0.31, 1.12) #
BSCM	1	1	100.0(2.5, 100.0)	7	7	100.0(59.0, 100.0)	1.00(0.18, 1.30) #
BSAL	0	0	-	7	7	100.0(59.0, 100.0)	-
BSM	0	0	-	16	18	88.9(65.3, 98.6)	-
BSCtoC	0	0	-	15	17	88.2(63.6, 98.5)	-
BSC	3	3	100.0(29.2, 100.0)	18	21	85.7(63.7, 97.0)	1.17(0.47, 1.38) #
BSSL	0	0	-	33	35	94.3(80.8, 99.3)	-
BSHC/BSOS	0	0	-	8	11	72.7(39.0, 94.0)	-
<b>Total</b>	<b>6</b>	<b>6</b>	<b>100.0(54.1, 100.0)</b>	<b>129</b>	<b>142</b>	<b>90.8(84.9, 95.0)</b>	<b>1.10(0.65, 1.13) #</b>
<b>50–69 years</b>							
BSWN	6	6	100.0(54.1, 100.0)	89	105	84.8(76.4, 91.0)	1.18(0.70, 1.24) #
BSCM	11	13	84.6(54.6, 98.1)	34	44	77.3(62.2, 88.5)	1.10(0.83, 1.45)
BSAL	3	3	100.0(29.2, 100.0)	28	31	90.3(74.2, 98.0)	1.11(0.45, 1.22) #
BSM	1	1	100.0(2.5, 100.0)	71	79	89.9(81.0, 95.5)	1.11(0.18, 1.13) #
BSCtoC	1	1	100.0(2.5, 100.0)	33	47	70.2(55.1, 82.7)	1.42(0.23, 1.56) #
BSC	5	5	100.0(47.8, 100.0)	51	62	82.3(70.5, 90.8)	1.22(0.66, 1.32) #
BSSL	0	0	-	99	107	92.5(85.8, 96.7)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	32	42	76.2(60.5, 87.9)	1.31(0.21, 1.43) #
<b>Total</b>	<b>28</b>	<b>30</b>	<b>93.3(77.9, 99.2)</b>	<b>437</b>	<b>517</b>	<b>84.5(81.1, 87.5)</b>	<b>1.10(1.00, 1.22)</b>

Ratios below one are unfavourable to Pacific women. Target >50% for women aged 50–69 years.

**Table 4e.c: Proportion of DCIS ≤ 20mm having BCS, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	No. of DCIS ≤20mm having BCS	No. of DCIS ≤ 20mm who are operated on	% of DCIS ≤20mm who have BCS (95% CI)	No. of DCIS ≤20mm having BCS	No. of DCIS ≤ 20mm who are operated on	% of DCIS ≤20mm who have BCS (95% CI)
BSWN	9	9	100.0(66.4, 100.0)	49	58	84.5(72.6, 92.7)
BSCM	3	3	100.0(29.2, 100.0)	17	21	81.0(58.1, 94.6)
BSAL	3	3	100.0(29.2, 100.0)	10	10	100.0(69.2, 100.0)
BSM	6	7	85.7(42.1, 99.6)	32	37	86.5(71.2, 95.5)
BSCtoC	5	6	83.3(35.9, 99.6)	17	27	63.0(42.4, 80.6)
BSC	4	5	80.0(28.4, 99.5)	19	25	76.0(54.9, 90.6)
BSSL	14	16	87.5(61.7, 98.4)	47	52	90.4(79.0, 96.8)
BSHC/BSOS	5	6	83.3(35.9, 99.6)	13	17	76.5(50.1, 93.2)
<b>Total</b>	<b>49</b>	<b>55</b>	<b>89.1(77.8, 95.9)</b>	<b>204</b>	<b>247</b>	<b>82.6(77.3, 87.1)</b>

Target >50% for women aged 50–69 years.

## 4f Proportion of invasive cancers having breast conserving surgery

### Description:

The proportion of women diagnosed with invasive cancer, without a DCIS component, of pathological diameter  $\leq 20\text{mm}$  who have breast conserving surgery (BCS).

### Target for women aged 50–69 years:


The majority ( $>50\%$ ) of screen-detected invasive cancers  $\leq 20\text{mm}$  are treated by BCS

**Table 4f.a: Proportion of invasive cancers  $\leq 20\text{mm}$ , without DCIS, having BCS, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/non-Māori ratio (95% CI)
	No. of invasive cancers without DCIS $\leq 20\text{mm}$ having BCS	No. of invasive cancers without DCIS $\leq 20\text{mm}$ who are operated on	% of invasive cancers without DCIS $\leq 20\text{mm}$ who have BCS (95% CI)	No. of invasive cancers, without DCIS $\leq 20\text{mm}$ having BCS	No. of invasive cancers without DCIS $\leq 20\text{mm}$ who are operated on	% of invasive cancers, without DCIS $\leq 20\text{mm}$ who have BCS (95% CI)	
<b>45–49 years</b>							
BSWN	5	6	83.3(35.9, 99.6)	9	11	81.8(48.2, 97.7)	1.02 (0.65, 1.60)
BSCM	1	1	100.0(2.5, 100.0)	4	4	100.0(39.8, 100.0)	1.00 (0.19, 1.63) #
BSAL	2	3	66.7(9.4, 99.2)	5	6	83.3(35.9, 99.6)	0.80 (0.33, 1.92)
BSM	3	3	100.0(29.2, 100.0)	9	10	90.0(55.5, 99.7)	1.11 (0.47, 1.49) #
BSCtoC	2	2	100.0(15.8, 100.0)	4	6	66.7(22.3, 95.7)	1.50 (0.44, 2.80) #
BSC	1	1	100.0(2.5, 100.0)	9	9	100.0(66.4, 100.0)	1.00 (0.17, 1.21) #
BSSL	2	2	100.0(15.8, 100.0)	8	10	80.0(44.4, 97.5)	1.25 (0.38, 1.75) #
BSHC/BSOS	0	0	-	4	5	80.0(28.4, 99.5)	-
<b>Total</b>	<b>16</b>	<b>18</b>	<b>88.9(65.3, 98.6)</b>	<b>52</b>	<b>61</b>	<b>85.2(73.8, 93.0)</b>	<b>1.04 (0.86, 1.27)</b>
<b>50–69 years</b>							
BSWN	21	25	84.0(63.9, 95.5)	89	105	84.8(76.4, 91.0)	0.99 (0.82, 1.20)
BSCM	10	14	71.4(41.9, 91.6)	27	37	73.0(55.9, 86.2)	0.98 (0.67, 1.44)
BSAL	3	4	75.0(19.4, 99.4)	53	61	86.9(75.8, 94.2)	0.86 (0.49, 1.53)
BSM	24	26	92.3(74.9, 99.1)	92	106	86.8(78.8, 92.6)	1.06 (0.93, 1.22)
BSCtoC	17	24	70.8(48.9, 87.4)	62	84	73.8(63.1, 82.8)	0.96 (0.72, 1.28)
BSC	8	9	88.9(51.8, 99.7)	46	54	85.2(72.9, 93.4)	1.04 (0.81, 1.35)
BSSL	6	7	85.7(42.1, 99.6)	72	91	79.1(69.3, 86.9)	1.08 (0.79, 1.49)
BSHC/BSOS	0	0	-	35	52	67.3(52.9, 79.7)	-
<b>Total</b>	<b>89</b>	<b>109</b>	<b>81.7(73.1, 88.4)</b>	<b>476</b>	<b>590</b>	<b>80.7(77.3, 83.8)</b>	<b>1.01 (0.92, 1.12)</b>

Ratios below one are unfavourable to Māori. Target  $>50\%$  for women aged 50–69 years.

**Figure 4f.a: Trends in the proportion of women with invasive cancers  $\leq 20$ mm, without DCIS, having BCS, total women aged 50–69 years, July 2008 to June 2014**



Note: No Māori women had an invasive breast cancer  $\leq 20$ mm without DCIS between July 2011 and June 2014 in the BSAL region.

**Table 4f.b: Proportion of invasive cancers  $\leq 20$ mm, without DCIS, having BCS, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers without DCIS $\leq 20$ mm having BCS	No. of invasive cancers without DCIS $\leq 20$ mm who are operated on	% of invasive cancers without DCIS $\leq 20$ mm who have BCS (95% CI)	No. of invasive cancers, without DCIS $\leq 20$ mm having BCS	No. of invasive cancers without DCIS $\leq 20$ mm who are operated on	% of invasive cancers, without DCIS $\leq 20$ mm who have BCS (95% CI)	
<b>45–49 years</b>							
BSWN	0	0	-	9	11	81.8 (48.2, 97.7)	-
BSCM	1	1	100.0(2.5, 100.0)	3	3	100.0(29.2, 100.0)	1.00(0.19, 1.91) #
BSAL	0	0	-	5	6	83.3 (35.9, 99.6)	-
BSM	0	0	-	9	10	90.0 (55.5, 99.7)	-
BSCtoC	0	0	-	4	6	66.7 (22.3, 95.7)	-
BSC	1	1	100.0(2.5, 100.0)	8	8	100.0(63.1, 100.0)	1.00(0.17, 1.25) #
BSSL	0	0	-	8	10	80.0 (44.4, 97.5)	-
BSHC/BSOS	0	0	-	4	5	80.0 (28.4, 99.5)	-
<b>Total</b>	<b>2</b>	<b>2</b>	<b>100.0(15.8, 100.0)</b>	<b>50</b>	<b>59</b>	<b>84.7 (73.0, 92.8)</b>	<b>1.18(0.35, 1.25) #</b>
<b>50–69 years</b>							
BSWN	3	3	100.0(29.2, 100.0)	86	102	84.3 (75.8, 90.8)	1.19(0.47, 1.23) #
BSCM	3	7	42.9(9.9, 81.6)	24	30	80.0 (61.4, 92.3)	0.54(0.22, 1.28)
BSAL	9	9	100.0(66.4, 100.0)	44	52	84.6 (71.9, 93.1)	1.18(0.82, 1.31) #
BSM	1	1	100.0(2.5, 100.0)	91	105	86.7 (78.6, 92.5)	1.15(0.18, 1.17) #
BSCtoC	0	1	0.0(0.0, 97.5)	62	83	74.7 (64.0, 83.6)	0.00(0.00, 5.09)
BSC	3	4	75.0(19.4, 99.4)	43	50	86.0 (73.3, 94.2)	0.87(0.49, 1.55)
BSSL	1	1	100.0(2.5, 100.0)	71	90	78.9 (69.0, 86.8)	1.27(0.20, 1.31) #
BSHC/BSOS	0	0	-	35	52	67.3 (52.9, 79.7)	-
<b>Total</b>	<b>20</b>	<b>26</b>	<b>76.9(56.4, 91.0)</b>	<b>456</b>	<b>564</b>	<b>80.9 (77.4, 84.0)</b>	<b>0.95(0.77, 1.18)</b>


Ratios below one are unfavourable to Māori. Target >50% for women aged 50–69 years.

**Table 4f.c: Proportion of invasive cancers  $\leq 20$ mm, without DCIS, having BCS, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	No. of invasive cancers without DCIS $\leq 20$ mm having BCS	No. of invasive cancers without DCIS $\leq 20$ mm who are operated on	% of invasive cancers without DCIS $\leq 20$ mm who have BCS (95% CI)	No. of invasive cancers, without DCIS $\leq 20$ mm having BCS	No. of invasive cancers without DCIS $\leq 20$ mm who are operated on	% of invasive cancers, without DCIS $\leq 20$ mm who have BCS (95% CI)
BSWN	3	4	75.0(19.4, 99.4)	45	53	84.9(72.4, 93.3)
BSCM	3	3	100.0(29.2, 100.0)	14	21	66.7(43.0, 85.4)
BSAL	2	2	100.0(15.8, 100.0)	19	23	82.6(61.2, 95.0)
BSM	7	7	100.0(59.0, 100.0)	52	59	88.1(77.1, 95.1)
BSCtoC	2	4	50.0(6.8, 93.2)	30	42	71.4(55.4, 84.3)
BSC	4	4	100.0(39.8, 100.0)	18	22	81.8(59.7, 94.8)
BSSL	7	8	87.5(47.3, 99.7)	34	43	79.1(64.0, 90.0)
BSHC/BSOS	0	1	0.0(0.0, 97.5)	23	29	79.3(60.3, 92.0)
<b>Total</b>	<b>28</b>	<b>33</b>	<b>84.8(68.1, 94.9)</b>	<b>235</b>	<b>292</b>	<b>80.5(75.5, 84.9)</b>

Target >50% for women aged 50–69 years.

**Figure 4f.b: Trends in the proportion of women with invasive cancers  $\leq 20$ mm, without DCIS, having BCS, total women aged 50–69 years, July 2008 to June 2014**



## 4g Proportion of women with invasive cancer having radiotherapy

### Description:

The proportion of women diagnosed with invasive cancer, who have breast conserving surgery (BCS) who go on to have radiotherapy

### Target for women aged 50–69 years:

≥95%

Table 4g.a: Proportion of invasive cancers, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)	
<b>45–49 years</b>							
BSWN	21	23	91.3(72.0, 98.9)	62	65	95.4(87.1, 99.0)	0.96(0.83, 1.10)
BSCM	9	10	90.0(55.5, 99.7)	37	37	100.0(90.5, 100.0)	0.90(0.60, 1.02) #
BSAL	4	7	57.1(18.4, 90.1)	34	41	82.9(67.9, 92.8)	0.69(0.36, 1.33)
BSM	20	23	87.0(66.4, 97.2)	68	74	91.9(83.2, 97.0)	0.95(0.80, 1.12)
BSCtoC	10	11	90.9(58.7, 99.8)	37	40	92.5(79.6, 98.4)	0.98(0.80, 1.21)
BSC	9	9	100.0(66.4, 100.0)	56	56	100.0(93.6, 100.0)	1.00(0.70, 1.03) #
BSSL	17	17	100.0(80.5, 100.0)	70	72	97.2(90.3, 99.7)	1.03(0.85, 1.08) #
BSHC/BSOS	2	2	100.0(15.8, 100.0)	29	30	96.7(82.8, 99.9)	1.03(0.31, 1.10) #
<b>Total</b>	<b>92</b>	<b>102</b>	<b>90.2(82.7, 95.2)</b>	<b>393</b>	<b>415</b>	<b>94.7(92.1, 96.6)</b>	<b>0.95(0.89, 1.02)</b>
<b>50–69 years</b>							
BSWN	64	67	95.5(87.5, 99.1)	379	403	94.0(91.3, 96.1)	1.02(0.96, 1.08)
BSCM	54	57	94.7(85.4, 98.9)	163	177	92.1(87.1, 95.6)	1.03(0.95, 1.11)
BSAL	12	15	80.0(51.9, 95.7)	164	213	77.0(70.8, 82.5)	1.04(0.80, 1.35)
BSM	118	129	91.5(85.3, 95.7)	383	418	91.6(88.5, 94.1)	1.00(0.94, 1.06)
BSCtoC	56	59	94.9(85.9, 98.9)	245	262	93.5(89.8, 96.2)	1.02(0.95, 1.09)
BSC	30	30	100.0(88.4, 100.0)	242	247	98.0(95.3, 99.3)	1.02(0.91, 1.04) #
BSSL	22	23	95.7(78.1, 99.9)	471	480	98.1(96.5, 99.1)	0.97(0.89, 1.06)
BSHC/BSOS	4	4	100.0(39.8, 100.0)	159	169	94.1(89.4, 97.1)	1.06(0.51, 1.08) #
<b>Total</b>	<b>360</b>	<b>384</b>	<b>93.8(90.8, 96.0)</b>	<b>2,206</b>	<b>2,369</b>	<b>93.1(92.0, 94.1)</b>	<b>1.01(0.98, 1.04)</b>

Ratios below one are unfavourable to Māori. Shaded boxes show the confidence interval excludes the target of ≥95%. Target is ≥95% for women aged 50–69 years.

**Table 4g.b: Proportion of invasive cancers, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)	
<b>45–49 years</b>							
BSWN	1	1	100.0(2.5, 100.0)	61	64	95.3(86.9, 99.0)	1.05(0.17, 1.06) #
BSCM	10	10	100.0(69.2, 100.0)	27	27	100.0(87.2, 100.0)	1.00(0.74, 1.09) #
BSAL	3	4	75.0(19.4, 99.4)	31	37	83.8(68.0, 93.8)	0.90(0.50, 1.60)
BSM	2	2	100.0(15.8, 100.0)	66	72	91.7(82.7, 96.9)	1.09(0.32, 1.12) #
BSCtoC	0	1	0.0(0.0, 97.5)	37	39	94.9(82.7, 99.4)	0.00(0.00, 4.09)
BSC	3	3	100.0(29.2, 100.0)	53	53	100.0(93.3, 100.0)	1.00(0.40, 1.02) #
BSSL	0	0	-	70	72	97.2(90.3, 99.7)	-
BSHC/BSOS	0	0	-	29	30	96.7(82.8, 99.9)	-
<b>Total</b>	<b>19</b>	<b>21</b>	<b>90.5(69.6, 98.8)</b>	<b>374</b>	<b>394</b>	<b>94.9(92.3, 96.9)</b>	<b>0.95(0.83, 1.10)</b>
<b>50–69 years</b>							
BSWN	18	22	81.8(59.7, 94.8)	361	381	94.8(92.0, 96.8)	0.86(0.71, 1.05)
BSCM	18	21	85.7(63.7, 97.0)	145	156	92.9(87.7, 96.4)	0.92(0.77, 1.10)
BSAL	15	24	62.5(40.6, 81.2)	149	189	78.8(72.3, 84.4)	0.79(0.58, 1.09)
BSM	9	9	100.0(66.4, 100.0)	374	409	91.4(88.3, 94.0)	1.09(0.76, 1.11) #
BSCtoC	0	1	0.0(0.0, 97.5)	245	261	93.9(90.2, 96.5)	0.00(0.00, 3.96)
BSC	10	10	100.0(69.2, 100.0)	232	237	97.9(95.1, 99.3)	1.02(0.73, 1.03) #
BSSL	4	4	100.0(39.8, 100.0)	467	476	98.1(96.4, 99.1)	1.02(0.49, 1.02) #
BSHC/BSOS	1	1	100.0(2.5, 100.0)	158	168	94.0(89.3, 97.1)	1.06(0.17, 1.06) #
<b>Total</b>	<b>75</b>	<b>92</b>	<b>81.5(72.1, 88.9)</b>	<b>2,131</b>	<b>2,277</b>	<b>93.6(92.5, 94.6)</b>	<b>0.87(0.79, 0.96)</b>

Ratios below one are unfavourable to Pacific women. Shaded boxes show the confidence interval excludes the target of ≥95%. Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women. Target is ≥95% for women aged 50–69 years.

**Table 4g.c: Proportion of invasive cancers, having BCS and having radiotherapy, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)	No. of invasive cancers having BCS who have radiotherapy	No. of invasive cancers having BCS	% of invasive cancers having BCS who have radiotherapy (95% CI)
BSWN	28	31	90.3(74.2, 98.0)	183	193	94.8(90.7, 97.5)
BSCM	17	17	100.0(80.5, 100.0)	76	85	89.4(80.8, 95.0)
BSAL	14	18	77.8(52.4, 93.6)	69	92	75.0(64.9, 83.4)
BSM	38	38	100.0(90.7, 100.0)	241	258	93.4(89.7, 96.1)
BSCtoC	23	26	88.5(69.8, 97.6)	125	131	95.4(90.3, 98.3)
BSC	27	27	100.0(87.2, 100.0)	103	105	98.1(93.3, 99.8)
BSSL	46	47	97.9(88.7, 99.9)	221	227	97.4(94.3, 99.0)
BSHC/BSOS	12	12	100.0(73.5, 100.0)	77	82	93.9(86.3, 98.0)
<b>Total</b>	<b>205</b>	<b>216</b>	<b>94.9(91.1, 97.4)</b>	<b>1,095</b>	<b>1,173</b>	<b>93.4(91.8, 94.7)</b>

Shaded boxes show the confidence interval excludes the target of ≥95%. Target ≥95% for women aged 50–69 years.

## 4h Proportion of women with DCIS having radiotherapy

### Description:

The proportion of women diagnosed solely with DCIS, who have Breast Conserving Surgery (BCS), who go on to have radiotherapy.

### Target:

No target.

**Table 4h.a: Proportion of women with DCIS, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)	
<b>45–49 years</b>							
BSWN	2	3	66.7(9.4, 99.2)	27	39	69.2(52.4, 83.0)	0.96(0.42, 2.20)
BSCM	1	3	33.3(0.8, 90.6)	9	11	81.8(48.2, 97.7)	0.41(0.08, 2.07)
BSAL	1	2	50.0(1.3, 98.7)	11	21	52.4(29.8, 74.3)	0.95(0.23, 4.05)
BSM	7	8	87.5(47.3, 99.7)	13	26	50.0(29.9, 70.1)	1.75(1.10, 2.79)
BSCtoC	0	2	0.0(0.0, 84.2)	9	18	50.0(26.0, 74.0)	0.00(0.00, 4.56)
BSC	0	0	-	11	28	39.3(21.5, 59.4)	-
BSSL	1	2	50.0(1.3, 98.7)	25	37	67.6(50.2, 82.0)	0.74(0.18, 3.01)
BSHC/BSOS	0	0	-	7	13	53.8(25.1, 80.8)	-
<b>Total</b>	<b>12</b>	<b>20</b>	<b>60.0(36.1, 80.9)</b>	<b>112</b>	<b>193</b>	<b>58.0(50.7, 65.1)</b>	<b>1.03(0.71, 1.51)</b>
<b>50–69 years</b>							
BSWN	8	15	53.3(26.6, 78.7)	84	127	66.1(57.2, 74.3)	0.81(0.49, 1.32)
BSCM	3	4	75.0(19.4, 99.4)	43	65	66.2(53.4, 77.4)	1.13(0.63, 2.05)
BSAL	1	5	20.0(0.5, 71.6)	31	69	44.9(32.9, 57.4)	0.45(0.08, 2.62)
BSM	15	17	88.2(63.6, 98.5)	75	115	65.2(55.8, 73.9)	1.35(1.09, 1.68)
BSCtoC	2	4	50.0(6.8, 93.2)	26	43	60.5(44.4, 75.0)	0.83(0.30, 2.27)
BSC	5	7	71.4(29.0, 96.3)	33	67	49.3(36.8, 61.8)	1.45(0.86, 2.46)
BSSL	4	7	57.1(18.4, 90.1)	98	131	74.8(66.5, 82.0)	0.76(0.40, 1.46)
BSHC/BSOS	1	3	33.3(0.8, 90.6)	27	41	65.9(49.4, 79.9)	0.51(0.10, 2.55)
<b>Total</b>	<b>39</b>	<b>62</b>	<b>62.9(49.7, 74.8)</b>	<b>417</b>	<b>658</b>	<b>63.4(59.6, 67.1)</b>	<b>0.99(0.81, 1.21)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori women

**Table 4h.b: Proportion of women with DCIS, having BCS and having radiotherapy, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)	
<b>45–49 years</b>							
BSWN	2	2	100.0(15.8, 100.0)	25	37	67.6(50.2, 82.0)	1.48(0.43, 1.72) #
BSCM	1	1	100.0(2.5, 100.0)	8	10	80.0(44.4, 97.5)	1.25(0.21, 1.68) #
BSAL	0	0	-	11	21	52.4(29.8, 74.3)	-
BSM	0	0	-	13	26	50.0(29.9, 70.1)	-
BSCtoC	0	0	-	9	18	50.0(26.0, 74.0)	-
BSC	0	3	0.0(0.0, 70.8)	11	25	44.0(24.4, 65.1)	0.00(0.00, 3.32)
BSSL	0	0	-	25	37	67.6(50.2, 82.0)	-
BSHC/BSOS	0	0	-	7	13	53.8(25.1, 80.8)	-
<b>Total</b>	<b>3</b>	<b>6</b>	<b>50.0(11.8, 88.2)</b>	<b>109</b>	<b>187</b>	<b>58.3(50.9, 65.4)</b>	<b>0.86(0.38, 1.93)</b>
<b>50–69 years</b>							
BSWN	4	9	44.4(13.7, 78.8)	80	118	67.8(58.6, 76.1)	0.66(0.31, 1.38)
BSCM	9	14	64.3(35.1, 87.2)	34	51	66.7(52.1, 79.2)	0.96(0.62, 1.49)
BSAL	3	4	75.0(19.4, 99.4)	28	65	43.1(30.8, 56.0)	1.74(0.93, 3.27)
BSM	1	2	50.0(1.3, 98.7)	74	113	65.5(56.0, 74.2)	0.76(0.19, 3.07)
BSCtoC	1	1	100.0(2.5, 100.0)	25	42	59.5(43.3, 74.4)	1.68(0.26, 1.92) #
BSC	2	6	33.3(4.3, 77.7)	31	61	50.8(37.7, 63.9)	0.66(0.21, 2.09)
BSSL	0	0	-	98	131	74.8(66.5, 82.0)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	26	40	65.0(48.3, 79.4)	1.54(0.24, 1.74) #
<b>Total</b>	<b>21</b>	<b>37</b>	<b>56.8(39.5, 72.9)</b>	<b>396</b>	<b>621</b>	<b>63.8(59.8, 67.6)</b>	<b>0.89(0.67, 1.19)</b>

**Table 4h.c: Proportion of women with DCIS, having BCS and having radiotherapy, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)	No. of DCIS, having BCS, who have radiotherapy	No. of DCIS, having BCS	% of DCIS, having BCS, who have radiotherapy (95% CI)
BSWN	11	15	73.3(44.9, 92.2)	35	62	56.5(43.3, 69.0)
BSCM	3	5	60.0(14.7, 94.7)	15	23	65.2(42.7, 83.6)
BSAL	5	9	55.6(21.2, 86.3)	12	25	48.0(27.8, 68.7)
BSM	10	14	71.4(41.9, 91.6)	39	62	62.9(49.7, 74.8)
BSCtoC	5	6	83.3(35.9, 99.6)	14	22	63.6(40.7, 82.8)
BSC	4	7	57.1(18.4, 90.1)	16	26	61.5(40.6, 79.8)
BSSL	9	15	60.0(32.3, 83.7)	52	69	75.4(63.5, 84.9)
BSHC/BSOS	4	9	44.4(13.7, 78.8)	8	17	47.1(23.0, 72.2)
<b>Total</b>	<b>51</b>	<b>80</b>	<b>63.7(52.2, 74.2)</b>	<b>191</b>	<b>306</b>	<b>62.4(56.7, 67.9)</b>

## 4i Proportion of women with invasive cancer having chemotherapy

### Description:

The proportion of women diagnosed with invasive cancer who have chemotherapy, reported by disease character groups.

**Table 4i.a: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of invasive cancers in group having chemotherapy	No. of invasive cancers, in group	% of invasive cancers, in group, having chemotherapy	No. of invasive cancers, in group, having chemotherapy	No. of invasive cancers, in group	% of invasive cancers, in group having chemotherapy	
<b>Group 1: Node positive, ER/PR negative</b>							
BSWN	0	0	-	3	3	100.0(29.2, 100.0)	-
BSCM	0	0	-	2	2	100.0(15.8, 100.0)	-
BSAL	1	1	100.0(2.5, 100.0)	0	1	0.0(0.0, 97.5)	Inf(0.39, 52.98) #
BSM	0	0	-	3	3	100.0(29.2, 100.0)	-
BSCtoC	0	0	-	1	1	100.0(2.5, 100.0)	-
BSC	0	0	-	1	1	100.0(2.5, 100.0)	-
BSSL	0	0	-	2	2	100.0(15.8, 100.0)	-
BSHC/BSOS	0	0	-	1	1	100.0(2.5, 100.0)	-
<b>Total</b>	<b>1</b>	<b>1</b>	<b>100.0(2.5, 100.0)</b>	<b>13</b>	<b>14</b>	<b>92.9(66.1, 99.8)</b>	<b>1.08(0.18, 1.25) #</b>
<b>Group 2: Node negative, high risk, and ER/PR negative</b>							
BSWN	3	4	75.0(19.4, 99.4)	16	18	88.9(65.3, 98.6)	0.84(0.47, 1.52)
BSCM	1	1	100.0(2.5, 100.0)	3	7	42.9(9.9, 81.6)	2.33(0.34, 4.76) #
BSAL	1	2	50.0(1.3, 98.7)	1	2	50.0(1.3, 98.7)	1.00(0.14, 7.10)
BSM	0	0	-	2	3	66.7(9.4, 99.2)	-
BSCtoC	0	1	0.0(0.0, 97.5)	1	2	50.0(1.3, 98.7)	0.00(0.00, 78.00)
BSC	0	0	-	3	4	75.0(19.4, 99.4)	-
BSSL	1	2	50.0(1.3, 98.7)	8	9	88.9(51.8, 99.7)	0.56(0.14, 2.29)
BSHC/BSOS	0	0	-	3	5	60.0(14.7, 94.7)	-
<b>Total</b>	<b>6</b>	<b>10</b>	<b>60.0(26.2, 87.8)</b>	<b>37</b>	<b>50</b>	<b>74.0(59.7, 85.4)</b>	<b>0.81(0.48, 1.38)</b>
<b>Group 3: Node positive, either ER or PR positive</b>							
BSWN	2	6	33.3(4.3, 77.7)	26	37	70.3(53.0, 84.1)	0.47(0.15, 1.50)
BSCM	5	9	55.6(21.2, 86.3)	20	29	69.0(49.2, 84.7)	0.81(0.43, 1.52)
BSAL	2	2	100.0(15.8, 100.0)	16	21	76.2(52.8, 91.8)	1.31(0.39, 1.59) #
BSM	8	11	72.7(39.0, 94.0)	18	25	72.0(50.6, 87.9)	1.01(0.65, 1.56)
BSCtoC	8	10	80.0(44.4, 97.5)	14	19	73.7(48.8, 90.9)	1.09(0.72, 1.64)
BSC	3	4	75.0(19.4, 99.4)	23	32	71.9(53.3, 86.3)	1.04(0.57, 1.91)
BSSL	6	7	85.7(42.1, 99.6)	31	35	88.6(73.3, 96.8)	0.97(0.70, 1.34)
BSHC/BSOS	1	1	100.0(2.5, 100.0)	14	16	87.5(61.7, 98.4)	1.14(0.19, 1.33) #
<b>Total</b>	<b>35</b>	<b>50</b>	<b>70.0(55.4, 82.1)</b>	<b>162</b>	<b>214</b>	<b>75.7(69.4, 81.3)</b>	<b>0.92(0.76, 1.13)</b>
<b>Group 4: Node negative, high risk-either ER or PR positive</b>							
BSWN	2	12	16.7(2.1, 48.4)	7	34	20.6(8.7, 37.9)	0.81(0.19, 3.37)
BSCM	3	5	60.0(14.7, 94.7)	9	31	29.0(14.2, 48.0)	2.07(0.84, 5.10)
BSAL	2	4	50.0(6.8, 93.2)	7	29	24.1(10.3, 43.5)	2.07(0.64, 6.70)
BSM	3	10	30.0(6.7, 65.2)	11	42	26.2(13.9, 42.0)	1.15(0.39, 3.35)
BSCtoC	4	7	57.1(18.4, 90.1)	15	25	60.0(38.7, 78.9)	0.95(0.46, 1.95)
BSC	2	5	40.0(5.3, 85.3)	8	37	21.6(9.8, 38.2)	1.85(0.54, 6.37)
BSSL	3	10	30.0(6.7, 65.2)	20	70	28.6(18.4, 40.6)	1.05(0.38, 2.90)
BSHC/BSOS	1	2	50.0(1.3, 98.7)	7	21	33.3(14.6, 57.0)	1.50(0.33, 6.80)
<b>Total</b>	<b>20</b>	<b>55</b>	<b>36.4(23.8, 50.4)</b>	<b>84</b>	<b>289</b>	<b>29.1(23.9, 34.7)</b>	<b>1.25(0.84, 1.85)</b>

Table 4i.b: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 50–69 years

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of invasive cancers in group having chemotherapy	No. of invasive cancers, in group	% of invasive cancers, in group, having chemotherapy	No. of invasive cancers, in group, having chemotherapy	No. of invasive cancers, in group	% of invasive cancers, in group having chemotherapy	
<b>Group 1: Node positive, ER/PR negative</b>							
BSWN	1	1	100.0(2.5, 100.0)	18	20	90.0(68.3, 98.8)	1.11(0.18, 1.24) #
BSCM	1	2	50.0(1.3, 98.7)	8	10	80.0(44.4, 97.5)	0.62(0.15, 2.59)
BSAL	1	1	100.0(2.5, 100.0)	10	11	90.9(58.7, 99.8)	1.10(0.19, 1.35) #
BSM	3	3	100.0(29.2, 100.0)	10	10	100.0(69.2, 100.0)	1.00(0.43, 1.24) #
BSCtoC	2	2	100.0(15.8, 100.0)	6	6	100.0(54.1, 100.0)	1.00(0.33, 1.43) #
BSC	0	0	-	13	13	100.0(75.3, 100.0)	-
BSSL	0	0	-	17	17	100.0(80.5, 100.0)	-
BSHC/BSOS	0	0	-	5	5	100.0(47.8, 100.0)	-
<b>Total</b>	<b>8</b>	<b>9</b>	<b>88.9(51.8, 99.7)</b>	<b>87</b>	<b>92</b>	<b>94.6(87.8, 98.2)</b>	<b>0.94(0.74, 1.19)</b>
<b>Group 2: Node negative, high risk, and ER/PR negative</b>							
BSWN	3	7	42.9(9.9, 81.6)	24	45	53.3(37.9, 68.3)	0.80(0.33, 1.97)
BSCM	2	4	50.0(6.8, 93.2)	11	20	55.0(31.5, 76.9)	0.91(0.32, 2.62)
BSAL	0	0	-	15	20	75.0(50.9, 91.3)	-
BSM	2	3	66.7(9.4, 99.2)	20	34	58.8(40.7, 75.4)	1.13(0.49, 2.65)
BSCtoC	4	6	66.7(22.3, 95.7)	13	31	41.9(24.5, 60.9)	1.59(0.79, 3.21)
BSC	2	3	66.7(9.4, 99.2)	16	35	45.7(28.8, 63.4)	1.46(0.61, 3.51)
BSSL	3	4	75.0(19.4, 99.4)	36	56	64.3(50.4, 76.6)	1.17(0.64, 2.12)
BSHC/BSOS	1	1	100.0(2.5, 100.0)	10	13	76.9(46.2, 95.0)	1.30(0.21, 1.66) #
<b>Total</b>	<b>17</b>	<b>28</b>	<b>60.7(40.6, 78.5)</b>	<b>145</b>	<b>254</b>	<b>57.1(50.8, 63.3)</b>	<b>1.06(0.78, 1.46)</b>
<b>Group 3: Node positive, either ER or PR positive</b>							
BSWN	10	23	43.5(23.2, 65.5)	38	102	37.3(27.9, 47.4)	1.17(0.69, 1.98)
BSCM	11	22	50.0(28.2, 71.8)	46	85	54.1(43.0, 65.0)	0.92(0.58, 1.47)
BSAL	1	6	16.7(0.4, 64.1)	24	61	39.3(27.1, 52.7)	0.42(0.07, 2.60)
BSM	12	42	28.6(15.7, 44.6)	51	110	46.4(36.8, 56.1)	0.62(0.37, 1.04)
BSCtoC	9	17	52.9(27.8, 77.0)	57	102	55.9(45.7, 65.7)	0.95(0.59, 1.53)
BSC	4	11	36.4(10.9, 69.2)	51	90	56.7(45.8, 67.1)	0.64(0.29, 1.43)
BSSL	4	8	50.0(15.7, 84.3)	71	134	53.0(44.2, 61.7)	0.94(0.46, 1.92)
BSHC/BSOS	2	2	100.0(15.8, 100.0)	41	58	70.7(57.3, 81.9)	1.41(0.42, 1.55) #
<b>Total</b>	<b>53</b>	<b>131</b>	<b>40.5(32.0, 49.4)</b>	<b>379</b>	<b>742</b>	<b>51.1(47.4, 54.7)</b>	<b>0.79(0.64, 0.99)</b>
<b>Group 4: Node negative, high risk-either ER or PR positive</b>							
BSWN	8	46	17.4(7.8, 31.4)	19	216	8.8(5.4, 13.4)	1.98(0.92, 4.24)
BSCM	4	36	11.1(3.1, 26.1)	22	138	15.9(10.3, 23.1)	0.70(0.26, 1.89)
BSAL	2	16	12.5(1.6, 38.3)	17	112	15.2(9.1, 23.2)	0.82(0.21, 3.24)
BSM	17	80	21.2(12.9, 31.8)	52	234	22.2(17.1, 28.1)	0.96(0.59, 1.55)
BSCtoC	9	55	16.4(7.8, 28.8)	38	178	21.3(15.6, 28.1)	0.77(0.40, 1.48)
BSC	1	21	4.8(0.1, 23.8)	24	142	16.9(11.1, 24.1)	0.28(0.04, 1.97)
BSSL	3	21	14.3(3.0, 36.3)	37	356	10.4(7.4, 14.0)	1.37(0.46, 4.09)
BSHC/BSOS	1	8	12.5(0.3, 52.7)	25	137	18.2(12.2, 25.7)	0.68(0.11, 4.43)
<b>Total</b>	<b>45</b>	<b>283</b>	<b>15.9(11.8, 20.7)</b>	<b>234</b>	<b>1,513</b>	<b>15.5(13.7, 17.4)</b>	<b>1.03(0.77, 1.38)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori women

**Table 4i.c: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy	
<b>Group 1: Node positive, and ER and PR negative</b>							
BSWN	0	0	-	3	3	100.0(29.2, 100.0)	-
BSCM	2	2	100.0(15.8, 100.0)	0	0	-	-
BSAL	0	0	-	0	1	0.0(0.0, 97.5)	-
BSM	1	1	100.0(2.5, 100.0)	2	2	100.0(15.8, 100.0)	1.00(0.21, 2.51) #
BSCtoC	0	0	-	1	1	100.0(2.5, 100.0)	-
BSC	0	0	-	1	1	100.0(2.5, 100.0)	-
BSSL	0	0	-	2	2	100.0(15.8, 100.0)	-
BSHC/BSOS	0	0	-	1	1	100.0(2.5, 100.0)	-
<b>Total</b>	<b>3</b>	<b>3</b>	<b>100.0(29.2, 100.0)</b>	<b>10</b>	<b>11</b>	<b>90.9(58.7, 99.8)</b>	<b>1.10(0.46, 1.43) #</b>
<b>Group 2: Node negative, high risk, and ER or PR negative</b>							
BSWN	1	1	100.0(2.5, 100.0)	15	17	88.2(63.6, 98.5)	1.13(0.19, 1.30) #
BSCM	1	1	100.0(2.5, 100.0)	2	6	33.3(4.3, 77.7)	3.00(0.39, 7.34) #
BSAL	0	0	-	1	2	50.0(1.3, 98.7)	-
BSM	0	0	-	2	3	66.7(9.4, 99.2)	-
BSCtoC	0	0	-	1	2	50.0(1.3, 98.7)	-
BSC	0	0	-	3	4	75.0(19.4, 99.4)	-
BSSL	0	0	-	8	9	88.9(51.8, 99.7)	-
BSHC/BSOS	0	0	-	3	5	60.0(14.7, 94.7)	-
<b>Total</b>	<b>2</b>	<b>2</b>	<b>100.0(15.8, 100.0)</b>	<b>35</b>	<b>48</b>	<b>72.9(58.2, 84.7)</b>	<b>1.37(0.40, 1.52) #</b>
<b>Group 3: Node positive, and either ER or PR positive</b>							
BSWN	2	2	100.0(15.8, 100.0)	24	35	68.6(50.7, 83.1)	1.46(0.43, 1.70) #
BSCM	6	10	60.0(26.2, 87.8)	14	19	73.7(48.8, 90.9)	0.81(0.46, 1.44)
BSAL	3	3	100.0(29.2, 100.0)	13	18	72.2(46.5, 90.3)	1.38(0.55, 1.80) #
BSM	0	1	0.0(0.0, 97.5)	18	24	75.0(53.3, 90.2)	0.00(0.00, 5.46)
BSCtoC	0	0	-	14	19	73.7(48.8, 90.9)	-
BSC	3	3	100.0(29.2, 100.0)	20	29	69.0(49.2, 84.7)	1.45(0.57, 1.76) #
BSSL	1	1	100.0(2.5, 100.0)	30	34	88.2(72.5, 96.7)	1.13(0.18, 1.21) #
BSHC/BSOS	0	0	-	14	16	87.5(61.7, 98.4)	-
<b>Total</b>	<b>15</b>	<b>20</b>	<b>75.0(50.9, 91.3)</b>	<b>147</b>	<b>194</b>	<b>75.8(69.1, 81.6)</b>	<b>0.99(0.76, 1.29)</b>
<b>Group 4: Node negative, high risk, and either ER or PR positive</b>							
BSWN	0	1	0.0(0.0, 97.5)	7	33	21.2(9.0, 38.9)	0.00(0.00, 22.90)
BSCM	1	6	16.7(0.4, 64.1)	8	25	32.0(14.9, 53.5)	0.52(0.08, 3.41)
BSAL	0	2	0.0(0.0, 84.2)	7	27	25.9(11.1, 46.3)	0.00(0.00, 9.37)
BSM	0	1	0.0(0.0, 97.5)	11	41	26.8(14.2, 42.9)	0.00(0.00, 16.34)
BSCtoC	0	0	-	15	25	60.0(38.7, 78.9)	-
BSC	2	3	66.7(9.4, 99.2)	6	34	17.6(6.8, 34.5)	3.78(1.28, 11.13)
BSSL	0	0	-	20	70	28.6(18.4, 40.6)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	6	20	30.0(11.9, 54.3)	3.33(0.48, 5.30) #
<b>Total</b>	<b>4</b>	<b>14</b>	<b>28.6(8.4, 58.1)</b>	<b>80</b>	<b>275</b>	<b>29.1(23.8, 34.8)</b>	<b>0.98(0.42, 2.29)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori.

Table 4i.d: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 50–69 years

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy	
<b>Group 1: Node positive, and ER and PR negative</b>							
BSWN	1	1	100.0(2.5, 100.0)	17	19	89.5(66.9, 98.7)	1.12(0.18, 1.26) #
BSCM	0	1	0.0(0.0, 97.5)	8	9	88.9(51.8, 99.7)	0.00(0.00, 5.27)
BSAL	3	3	100.0(29.2, 100.0)	7	8	87.5(47.3, 99.7)	1.14(0.48, 1.67) #
BSM	0	0	-	10	10	100.0(69.2, 100.0)	-
BSCtoC	0	0	-	6	6	100.0(54.1, 100.0)	-
BSC	0	0	-	13	13	100.0(75.3, 100.0)	-
BSSL	0	0	-	17	17	100.0(80.5, 100.0)	-
BSHC/BSOS	0	0	-	5	5	100.0(47.8, 100.0)	-
<b>Total</b>	<b>4</b>	<b>5</b>	<b>80.0(28.4, 99.5)</b>	<b>83</b>	<b>87</b>	<b>95.4(88.6, 98.7)</b>	<b>0.84(0.54, 1.30)</b>
<b>Group 2: Node negative, high risk, and ER or PR negative</b>							
BSWN	0	1	0.0(0.0, 97.5)	24	44	54.5(38.8, 69.6)	0.00(0.00, 7.31)
BSCM	2	5	40.0(5.3, 85.3)	9	15	60.0(32.3, 83.7)	0.67(0.21, 2.11)
BSAL	1	1	100.0(2.5, 100.0)	14	19	73.7(48.8, 90.9)	1.36(0.22, 1.64) #
BSM	1	1	100.0(2.5, 100.0)	19	33	57.6(39.2, 74.5)	1.74(0.27, 2.06) #
BSCtoC	0	0	-	13	31	41.9(24.5, 60.9)	-
BSC	0	1	0.0(0.0, 97.5)	16	34	47.1(29.8, 64.9)	0.00(0.00, 8.82)
BSSL	0	0	-	36	56	64.3(50.4, 76.6)	-
BSHC/BSOS	0	0	-	10	13	76.9(46.2, 95.0)	-
<b>Total</b>	<b>4</b>	<b>9</b>	<b>44.4(13.7, 78.8)</b>	<b>141</b>	<b>245</b>	<b>57.6(51.1, 63.8)</b>	<b>0.77(0.37, 1.62)</b>
<b>Group 3: Node positive, and either ER or PR positive</b>							
BSWN	3	8	37.5(8.5, 75.5)	35	94	37.2(27.5, 47.8)	1.01(0.40, 2.56)
BSCM	10	19	52.6(28.9, 75.6)	36	66	54.5(41.8, 66.9)	0.96(0.60, 1.56)
BSAL	3	8	37.5(8.5, 75.5)	21	53	39.6(26.5, 54.0)	0.95(0.36, 2.46)
BSM	1	2	50.0(1.3, 98.7)	50	108	46.3(36.7, 56.2)	1.08(0.27, 4.38)
BSCtoC	2	2	100.0(15.8, 100.0)	55	100	55.0(44.7, 65.0)	1.82(0.53, 1.99) #
BSC	3	7	42.9(9.9, 81.6)	48	83	57.8(46.5, 68.6)	0.74(0.31, 1.78)
BSSL	0	0	-	71	134	53.0(44.2, 61.7)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	40	57	70.2(56.6, 81.6)	1.42(0.23, 1.54) #
<b>Total</b>	<b>23</b>	<b>47</b>	<b>48.9(34.1, 63.9)</b>	<b>356</b>	<b>695</b>	<b>51.2(47.4, 55.0)</b>	<b>0.96(0.71, 1.29)</b>
<b>Group 4: Node negative, high risk, and either ER or PR positive</b>							
BSWN	0	14	0.0(0.0, 23.2)	19	202	9.4(5.8, 14.3)	0.00(0.00, 3.09)
BSCM	1	21	4.8(0.1, 23.8)	21	117	17.9(11.5, 26.1)	0.27(0.04, 1.87)
BSAL	2	15	13.3(1.7, 40.5)	15	97	15.5(8.9, 24.2)	0.86(0.22, 3.40)
BSM	3	7	42.9(9.9, 81.6)	49	227	21.6(16.4, 27.5)	1.99(0.81, 4.84)
BSCtoC	0	0	-	38	178	21.3(15.6, 28.1)	-
BSC	0	6	0.0(0.0, 45.9)	24	136	17.6(11.6, 25.1)	0.00(0.00, 3.77)
BSSL	2	5	40.0(5.3, 85.3)	35	351	10.0(7.0, 13.6)	4.01(1.31, 12.28)
BSHC/BSOS	0	1	0.0(0.0, 97.5)	25	136	18.4(12.3, 25.9)	0.00(0.00, 21.62)
<b>Total</b>	<b>8</b>	<b>69</b>	<b>11.6(5.1, 21.6)</b>	<b>226</b>	<b>1,444</b>	<b>15.7(13.8, 17.6)</b>	<b>0.74(0.38, 1.44)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori.

Table 4i.e: The proportion of women with invasive cancers who have chemotherapy, by disease character group, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years

Lead provider	45–49 years			50–69 years		
	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy	No. of invasive cancers in group having chemotherapy	No. of invasive cancers in group	% of invasive cancers in group having chemotherapy
<b>Group 1: Node positive, and ER and PR negative</b>						
BSWN	1	1	100.0(2.5, 100.0)	8	8	100.0(63.1, 100.0)
BSCM	1	1	100.0(2.5, 100.0)	2	2	100.0(15.8, 100.0)
BSAL	0	0	-	4	4	100.0(39.8, 100.0)
BSM	2	2	100.0(15.8, 100.0)	5	5	100.0(47.8, 100.0)
BSCtoC	0	0	-	1	1	100.0(2.5, 100.0)
BSC	1	1	100.0(2.5, 100.0)	7	7	100.0(59.0, 100.0)
BSSL	0	0	-	6	6	100.0(54.1, 100.0)
BSHC/BSOS	0	0	-	2	2	100.0(15.8, 100.0)
<b>Total</b>	<b>5</b>	<b>5</b>	<b>100.0(47.8, 100.0)</b>	<b>35</b>	<b>35</b>	<b>100.0(90.0, 100.0)</b>
<b>Group 2: Node negative, high risk, and ER or PR negative</b>						
BSWN	8	9	88.9(51.8, 99.7)	5	14	35.7(12.8, 64.9)
BSCM	2	3	66.7(9.4, 99.2)	5	8	62.5(24.5, 91.5)
BSAL	0	0	-	3	7	42.9(9.9, 81.6)
BSM	1	2	50.0(1.3, 98.7)	7	14	50.0(23.0, 77.0)
BSCtoC	1	2	50.0(1.3, 98.7)	5	11	45.5(16.7, 76.6)
BSC	2	3	66.7(9.4, 99.2)	9	14	64.3(35.1, 87.2)
BSSL	6	7	85.7(42.1, 99.6)	17	30	56.7(37.4, 74.5)
BSHC/BSOS	2	4	50.0(6.8, 93.2)	8	9	88.9(51.8, 99.7)
<b>Total</b>	<b>22</b>	<b>30</b>	<b>73.3(54.1, 87.7)</b>	<b>59</b>	<b>107</b>	<b>55.1(45.2, 64.8)</b>
<b>Group 3: Node positive, and either ER or PR positive</b>						
BSWN	11	19	57.9(33.5, 79.7)	16	51	31.4(19.1, 45.9)
BSCM	8	13	61.5(31.6, 86.1)	26	48	54.2(39.2, 68.6)
BSAL	9	10	90.0(55.5, 99.7)	15	36	41.7(25.5, 59.2)
BSM	11	15	73.3(44.9, 92.2)	36	83	43.4(32.5, 54.7)
BSCtoC	9	13	69.2(38.6, 90.9)	28	49	57.1(42.2, 71.2)
BSC	9	13	69.2(38.6, 90.9)	16	35	45.7(28.8, 63.4)
BSSL	18	20	90.0(68.3, 98.8)	36	64	56.2(43.3, 68.6)
BSHC/BSOS	4	6	66.7(22.3, 95.7)	18	27	66.7(46.0, 83.5)
<b>Total</b>	<b>79</b>	<b>109</b>	<b>72.5(63.1, 80.6)</b>	<b>191</b>	<b>393</b>	<b>48.6(43.6, 53.7)</b>
<b>Group 4: Node negative, high risk, and either ER or PR positive</b>						
BSWN	3	20	15.0(3.2, 37.9)	15	117	12.8(7.4, 20.3)
BSCM	5	19	26.3(9.1, 51.2)	10	65	15.4(7.6, 26.5)
BSAL	2	14	14.3(1.8, 42.8)	10	55	18.2(9.1, 30.9)
BSM	4	18	22.2(6.4, 47.6)	36	145	24.8(18.0, 32.7)
BSCtoC	8	11	72.7(39.0, 94.0)	25	99	25.3(17.1, 35.0)
BSC	5	18	27.8(9.7, 53.5)	10	59	16.9(8.4, 29.0)
BSSL	12	35	34.3(19.1, 52.2)	17	178	9.6(5.7, 14.9)
BSHC/BSOS	3	12	25.0(5.5, 57.2)	11	65	16.9(8.8, 28.3)
<b>Total</b>	<b>42</b>	<b>147</b>	<b>28.6(21.4, 36.6)</b>	<b>134</b>	<b>783</b>	<b>17.1(14.5, 19.9)</b>

## 4j Proportion of women with invasive cancer having endocrine therapy

### Description:

The proportion of women diagnosed with invasive cancer who have endocrine therapy reported by disease character group.

**Table 4j.a: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of invasive cancers, in group having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group having endocrine therapy	
<b>Group 1: Node positive and either ER or PR positive</b>							
BSWN	6	6	100.0 (54.1, 100.0)	35	37	94.6 (81.8, 99.3)	1.06 (0.64, 1.15) #
BSCM	9	9	100.0 (66.4, 100.0)	26	29	89.7 (72.6, 97.8)	1.12 (0.78, 1.29) #
BSAL	2	2	100.0 (15.8, 100.0)	20	21	95.2 (76.2, 99.9)	1.05 (0.32, 1.16) #
BSM	11	11	100.0 (71.5, 100.0)	23	25	92.0 (74.0, 99.0)	1.09 (0.81, 1.27) #
BSCtoC	10	10	100.0 (69.2, 100.0)	19	19	100.0 (82.4, 100.0)	1.00 (0.74, 1.14) #
BSC	4	4	100.0 (39.8, 100.0)	32	32	100.0 (89.1, 100.0)	1.00 (0.49, 1.05) #
BSSL	7	7	100.0 (59.0, 100.0)	34	35	97.1 (85.1, 99.9)	1.03 (0.66, 1.11) #
BSHC/BSOS	1	1	100.0 (2.5, 100.0)	15	16	93.8 (69.8, 99.8)	1.07 (0.18, 1.20) #
<b>Total</b>	<b>50</b>	<b>50</b>	<b>100.0 (92.9, 100.0)</b>	<b>204</b>	<b>214</b>	<b>95.3 (91.6, 97.7)</b>	<b>1.05 (0.97, 1.08) #</b>
<b>Group 2: Node negative, high risk, and either ER or PR positive</b>							
BSWN	10	12	83.3 (51.6, 97.9)	26	34	76.5 (58.8, 89.3)	1.09 (0.80, 1.49)
BSCM	4	5	80.0 (28.4, 99.5)	22	31	71.0 (52.0, 85.8)	1.13 (0.69, 1.85)
BSAL	3	4	75.0 (19.4, 99.4)	18	29	62.1 (42.3, 79.3)	1.21 (0.64, 2.28)
BSM	10	10	100.0 (69.2, 100.0)	41	42	97.6 (87.4, 99.9)	1.02 (0.75, 1.09) #
BSCtoC	6	7	85.7 (42.1, 99.6)	22	25	88.0 (68.8, 97.5)	0.97 (0.70, 1.36)
BSC	5	5	100.0 (47.8, 100.0)	31	37	83.8 (68.0, 93.8)	1.19 (0.65, 1.35) #
BSSL	7	10	70.0 (34.8, 93.3)	45	70	64.3 (51.9, 75.4)	1.09 (0.70, 1.69)
BSHC/BSOS	2	2	100.0 (15.8, 100.0)	12	21	57.1 (34.0, 78.2)	1.75 (0.50, 2.34) #
<b>Total</b>	<b>47</b>	<b>55</b>	<b>85.5 (73.3, 93.5)</b>	<b>217</b>	<b>289</b>	<b>75.1 (69.7, 80.0)</b>	<b>1.14 (1.00, 1.29)</b>
<b>Group 3: Node negative, low risk, and either ER or PR positive</b>							
BSWN	0	9	0.0 (0.0, 33.6)	8	36	22.2 (10.1, 39.2)	0.00 (0.00, 2.34)
BSCM	2	6	33.3 (4.3, 77.7)	3	13	23.1 (5.0, 53.8)	1.44 (0.32, 6.51)
BSAL	2	3	66.7 (9.4, 99.2)	3	19	15.8 (3.4, 39.6)	4.22 (1.14, 15.66)
BSM	6	8	75.0 (34.9, 96.8)	19	19	100.0 (82.4, 100.0)	0.75 (0.42, 1.00) #
BSCtoC	6	8	75.0 (34.9, 96.8)	11	16	68.8 (41.3, 89.0)	1.09 (0.65, 1.83)
BSC	2	3	66.7 (9.4, 99.2)	15	17	88.2 (63.6, 98.5)	0.76 (0.33, 1.71)
BSSL	2	6	33.3 (4.3, 77.7)	11	29	37.9 (20.7, 57.7)	0.88 (0.26, 2.99)
BSHC/BSOS	0	0	-	2	13	15.4 (1.9, 45.4)	-
<b>Total</b>	<b>20</b>	<b>43</b>	<b>46.5 (31.2, 62.3)</b>	<b>72</b>	<b>162</b>	<b>44.4 (36.6, 52.4)</b>	<b>1.05 (0.73, 1.51)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori women

**Table 4j.b: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Māori and non-Māori women aged 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	No. of invasive cancers, in group having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group having endocrine therapy	
<b>Group 1: Node positive, and either ER or PR positive</b>							
BSWN	22	23	95.7(78.1, 99.9)	95	102	93.1(86.4, 97.2)	1.03(0.93, 1.14)
BSCM	20	22	90.9(70.8, 98.9)	79	85	92.9(85.3, 97.4)	0.98(0.85, 1.13)
BSAL	5	6	83.3(35.9, 99.6)	56	61	91.8(81.9, 97.3)	0.91(0.63, 1.31)
BSM	40	42	95.2(83.8, 99.4)	107	110	97.3(92.2, 99.4)	0.98(0.91, 1.05)
BSCtoC	17	17	100.0(80.5, 100.0)	100	102	98.0(93.1, 99.8)	1.02(0.84, 1.05) #
BSC	11	11	100.0(71.5, 100.0)	89	90	98.9(94.0, 100.0)	1.01(0.75, 1.04) #
BSSL	7	8	87.5(47.3, 99.7)	129	134	96.3(91.5, 98.8)	0.91(0.70, 1.18)
BSHC/BSOS	2	2	100.0(15.8, 100.0)	58	58	100.0(93.8, 100.0)	1.00(0.30, 1.01) #
<b>Total</b>	<b>124</b>	<b>131</b>	<b>94.7(89.3, 97.8)</b>	<b>713</b>	<b>742</b>	<b>96.1(94.4, 97.4)</b>	<b>0.99(0.94, 1.03)</b>
<b>Group 2: Node negative, high risk, and either ER or PR positive</b>							
BSWN	32	46	69.6(54.2, 82.3)	161	216	74.5(68.2, 80.2)	0.93(0.76, 1.15)
BSCM	21	36	58.3(40.8, 74.5)	86	138	62.3(53.7, 70.4)	0.94(0.69, 1.27)
BSAL	10	16	62.5(35.4, 84.8)	72	112	64.3(54.7, 73.1)	0.97(0.65, 1.46)
BSM	72	80	90.0(81.2, 95.6)	224	234	95.7(92.3, 97.9)	0.94(0.87, 1.02)
BSCtoC	46	55	83.6(71.2, 92.2)	142	178	79.8(73.1, 85.4)	1.05(0.91, 1.20)
BSC	18	21	85.7(63.7, 97.0)	125	142	88.0(81.5, 92.9)	0.97(0.81, 1.17)
BSSL	18	21	85.7(63.7, 97.0)	217	356	61.0(55.7, 66.1)	1.41(1.16, 1.71)
BSHC/BSOS	5	8	62.5(24.5, 91.5)	81	137	59.1(50.4, 67.4)	1.06(0.61, 1.84)
<b>Total</b>	<b>222</b>	<b>283</b>	<b>78.4(73.2, 83.1)</b>	<b>1,108</b>	<b>1,513</b>	<b>73.2(70.9, 75.4)</b>	<b>1.07(1.00, 1.15)</b>
<b>Group 3: Node negative, low risk, and either ER or PR positive</b>							
BSWN	3	21	14.3(3.0, 36.3)	34	192	17.7(12.6, 23.9)	0.81(0.27, 2.40)
BSCM	3	30	10.0(2.1, 26.5)	6	79	7.6(2.8, 15.8)	1.32(0.35, 4.93)
BSAL	0	1	0.0(0.0, 97.5)	11	95	11.6(5.9, 19.8)	0.00(0.00, 37.85)
BSM	31	38	81.6(65.7, 92.3)	121	133	91.0(84.8, 95.3)	0.90(0.76, 1.05)
BSCtoC	11	19	57.9(33.5, 79.7)	58	107	54.2(44.3, 63.9)	1.07(0.70, 1.63)
BSC	11	14	78.6(49.2, 95.3)	65	96	67.7(57.4, 76.9)	1.16(0.85, 1.58)
BSSL	1	10	10.0(0.3, 44.5)	57	187	30.5(24.0, 37.6)	0.33(0.05, 2.13)
BSHC/BSOS	1	2	50.0(1.3, 98.7)	14	65	21.5(12.3, 33.5)	2.32(0.54, 10.01)
<b>Total</b>	<b>61</b>	<b>135</b>	<b>45.2(36.6, 54.0)</b>	<b>366</b>	<b>954</b>	<b>38.4(35.3, 41.5)</b>	<b>1.18(0.96, 1.44)</b>

Ratios in italics show a statistically significant difference between Māori and non-Māori.

**Table 4j.c: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers, in group having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group having endocrine therapy	
<b>Group 1: Node positive, and either ER or PR positive</b>							
BSWN	2	2	100.0(15.8, 100.0)	33	35	94.3(80.8, 99.3)	1.06(0.32, 1.12) #
BSCM	9	10	90.0(55.5, 99.7)	17	19	89.5(66.9, 98.7)	1.01(0.78, 1.30)
BSAL	3	3	100.0(29.2, 100.0)	17	18	94.4(72.7, 99.9)	1.06(0.44, 1.22) #
BSM	1	1	100.0(2.5, 100.0)	22	24	91.7(73.0, 99.0)	1.09(0.18, 1.18) #
BSCtoC	0	0	-	19	19	100.0(82.4, 100.0)	-
BSC	3	3	100.0(29.2, 100.0)	29	29	100.0(88.1, 100.0)	1.00(0.41, 1.05) #
BSSL	1	1	100.0(2.5, 100.0)	33	34	97.1(84.7, 99.9)	1.03(0.17, 1.07) #
BSHC/BSOS	0	0	-	15	16	93.8(69.8, 99.8)	-
<b>Total</b>	<b>19</b>	<b>20</b>	<b>95.0(75.1, 99.9)</b>	<b>185</b>	<b>194</b>	<b>95.4(91.4, 97.9)</b>	<b>1.00(0.90, 1.11)</b>
<b>Group 2: Node negative, high risk, and either ER or PR positive</b>							
BSWN	1	1	100.0(2.5, 100.0)	25	33	75.8(57.7, 88.9)	1.32(0.21, 1.47) #
BSCM	5	6	83.3(35.9, 99.6)	17	25	68.0(46.5, 85.1)	1.23(0.78, 1.92)
BSAL	0	2	0.0(0.0, 84.2)	18	27	66.7(46.0, 83.5)	0.00(0.00, 3.07)
BSM	1	1	100.0(2.5, 100.0)	40	41	97.6(87.1, 99.9)	1.03(0.17, 1.05) #
BSCtoC	0	0	-	22	25	88.0(68.8, 97.5)	-
BSC	3	3	100.0(29.2, 100.0)	28	34	82.4(65.5, 93.2)	1.21(0.49, 1.37) #
BSSL	0	0	-	45	70	64.3(51.9, 75.4)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	11	20	55.0(31.5, 76.9)	1.82(0.29, 2.38) #
<b>Total</b>	<b>11</b>	<b>14</b>	<b>78.6(49.2, 95.3)</b>	<b>206</b>	<b>275</b>	<b>74.9(69.4, 79.9)</b>	<b>1.05(0.79, 1.39)</b>
<b>Group 3: Node negative, low risk, and either ER or PR positive</b>							
BSWN	0	1	0.0(0.0, 97.5)	8	35	22.9(10.4, 40.1)	0.00(0.00, 20.50)
BSCM	2	3	66.7(9.4, 99.2)	1	10	10.0(0.3, 44.5)	6.67(0.88, 50.47)
BSAL	0	2	0.0(0.0, 84.2)	3	17	17.6(3.8, 43.4)	0.00(0.00, 20.57)
BSM	0	0	-	19	19	100.0(82.4, 100.0)	-
BSCtoC	1	1	100.0(2.5, 100.0)	10	15	66.7(38.4, 88.2)	1.50(0.24, 1.97) #
BSC	0	0	-	15	17	88.2(63.6, 98.5)	-
BSSL	0	0	-	11	29	37.9(20.7, 57.7)	-
BSHC/BSOS	0	0	-	2	13	15.4(1.9, 45.4)	-
<b>Total</b>	<b>3</b>	<b>7</b>	<b>42.9(9.9, 81.6)</b>	<b>69</b>	<b>155</b>	<b>44.5(36.5, 52.7)</b>	<b>0.96(0.40, 2.31)</b>

**Table 4j.d: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	No. of invasive cancers, in group having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group having endocrine therapy	
<b>Group 1: Node positive, and either ER or PR positive</b>							
BSWN	7	8	87.5(47.3, 99.7)	88	94	93.6(86.6, 97.6)	0.93(0.72, 1.22)
BSCM	18	19	94.7(74.0, 99.9)	61	66	92.4(83.2, 97.5)	1.03(0.90, 1.16)
BSAL	7	8	87.5(47.3, 99.7)	49	53	92.5(81.8, 97.9)	0.95(0.72, 1.24)
BSM	2	2	100.0(15.8, 100.0)	105	108	97.2(92.1, 99.4)	1.03(0.30, 1.03) #
BSCtoC	2	2	100.0(15.8, 100.0)	98	100	98.0(93.0, 99.8)	1.02(0.30, 1.03) #
BSC	7	7	100.0(59.0, 100.0)	82	83	98.8(93.5, 100.0)	1.01(0.65, 1.03) #
BSSL	0	0	-	129	134	96.3(91.5, 98.8)	-
BSHC/BSOS	1	1	100.0(2.5, 100.0)	57	57	100.0(93.7, 100.0)	1.00(0.16, 1.00) #
<b>Total</b>	<b>44</b>	<b>47</b>	<b>93.6(82.5, 98.7)</b>	<b>669</b>	<b>695</b>	<b>96.3(94.6, 97.5)</b>	<b>0.97(0.90, 1.05)</b>
<b>Group 2: Node negative, high risk, and either ER or PR positive</b>							
BSWN	12	14	85.7(57.2, 98.2)	149	202	73.8(67.1, 79.7)	1.16(0.92, 1.46)
BSCM	11	21	52.4(29.8, 74.3)	75	117	64.1(54.7, 72.8)	0.82(0.53, 1.26)
BSAL	11	15	73.3(44.9, 92.2)	61	97	62.9(52.5, 72.5)	1.17(0.83, 1.64)
BSM	7	7	100.0(59.0, 100.0)	217	227	95.6(92.0, 97.9)	1.05(0.66, 1.06) #
BSCtoC	0	0	-	142	178	79.8(73.1, 85.4)	-
BSC	5	6	83.3(35.9, 99.6)	120	136	88.2(81.6, 93.1)	0.94(0.66, 1.36)
BSSL	5	5	100.0(47.8, 100.0)	212	351	60.4(55.1, 65.6)	1.66(0.89, 1.72) #
BSHC/BSOS	0	1	0.0(0.0, 97.5)	81	136	59.6(50.8, 67.9)	0.00(0.00, 6.34)
<b>Total</b>	<b>51</b>	<b>69</b>	<b>73.9(61.9, 83.7)</b>	<b>1,057</b>	<b>1,444</b>	<b>73.2(70.8, 75.5)</b>	<b>1.01(0.87, 1.17)</b>
<b>Group 3: Node negative, low risk, and either ER or PR positive</b>							
BSWN	0	6	0.0(0.0, 45.9)	34	186	18.3(13.0, 24.6)	0.00(0.00, 3.55)
BSCM	1	9	11.1(0.3, 48.2)	5	70	7.1(2.4, 15.9)	1.56(0.20, 11.86)
BSAL	2	12	16.7(2.1, 48.4)	9	83	10.8(5.1, 19.6)	1.54(0.38, 6.28)
BSM	1	1	100.0(2.5, 100.0)	120	132	90.9(84.7, 95.2)	1.10(0.18, 1.10) #
BSCtoC	1	3	33.3(0.8, 90.6)	57	104	54.8(44.7, 64.6)	0.61(0.12, 3.04)
BSC	2	4	50.0(6.8, 93.2)	63	92	68.5(58.0, 77.8)	0.73(0.27, 1.96)
BSSL	2	2	100.0(15.8, 100.0)	55	185	29.7(23.2, 36.9)	3.36(0.97, 3.77) #
BSHC/BSOS	0	0	-	14	65	21.5(12.3, 33.5)	-
<b>Total</b>	<b>9</b>	<b>37</b>	<b>24.3(11.8, 41.2)</b>	<b>357</b>	<b>917</b>	<b>38.9(35.8, 42.2)</b>	<b>0.62(0.35, 1.11)</b>

Table 4j.e: Proportion of women diagnosed with invasive cancer who had endocrine therapy by disease character group, 2 years (July 2012–June 2014), total women aged 45–49 and 50–69 years

Lead provider	45–49 years			50–69 years		
	No. of invasive cancers, in group having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group, having endocrine therapy	No. of invasive cancers, in group	% of invasive cancers, in group having endocrine therapy
<b>Group 1: Node positive, and either ER or PR positive</b>						
BSWN	13	13	100.0(75.3, 100.0)	46	51	90.2(78.6, 96.7)
BSCM	10	10	100.0(69.2, 100.0)	46	48	95.8(85.7, 99.5)
BSAL	15	15	100.0(78.2, 100.0)	32	36	88.9(73.9, 96.9)
BSM	13	13	100.0(75.3, 100.0)	81	83	97.6(91.6, 99.7)
BSCtoC	13	13	100.0(75.3, 100.0)	49	49	100.0(92.7, 100.0)
BSC	20	20	100.0(83.2, 100.0)	35	35	100.0(90.0, 100.0)
BSSL	6	6	100.0(54.1, 100.0)	61	64	95.3(86.9, 99.0)
BSHC/BSOS	107	109	98.2(93.5, 99.8)	27	27	100.0(87.2, 100.0)
<b>Total</b>	<b>17</b>	<b>19</b>	<b>89.5(66.9, 98.7)</b>	<b>377</b>	<b>393</b>	<b>95.9(93.5, 97.7)</b>
<b>Group 2: Node negative, high risk, and either ER or PR positive</b>						
BSWN	15	20	75.0(50.9, 91.3)	91	117	77.8(69.2, 84.9)
BSCM	14	19	73.7(48.8, 90.9)	45	65	69.2(56.6, 80.1)
BSAL	9	14	64.3(35.1, 87.2)	40	55	72.7(59.0, 83.9)
BSM	18	18	100.0(81.5, 100.0)	138	145	95.2(90.3, 98.0)
BSCtoC	10	11	90.9(58.7, 99.8)	85	99	85.9(77.4, 92.0)
BSC	14	18	77.8(52.4, 93.6)	52	59	88.1(77.1, 95.1)
BSSL	21	35	60.0(42.1, 76.1)	114	178	64.0(56.5, 71.1)
BSHC/BSOS	7	12	58.3(27.7, 84.8)	40	65	61.5(48.6, 73.3)
<b>Total</b>	<b>108</b>	<b>147</b>	<b>73.5(65.6, 80.4)</b>	<b>605</b>	<b>783</b>	<b>77.3(74.2, 80.2)</b>
<b>Group 3: Node negative, low risk, and either ER or PR positive</b>						
BSWN	3	14	21.4(4.7, 50.8)	13	86	15.1(8.3, 24.5)
BSCM	3	7	42.9(9.9, 81.6)	6	42	14.3(5.4, 28.5)
BSAL	2	5	40.0(5.3, 85.3)	4	35	11.4(3.2, 26.7)
BSM	9	9	100.0(66.4, 100.0)	67	75	89.3(80.1, 95.3)
BSCtoC	11	14	78.6(49.2, 95.3)	28	50	56.0(41.3, 70.0)
BSC	8	8	100.0(63.1, 100.0)	34	43	79.1(64.0, 90.0)
BSSL	6	21	28.6(11.3, 52.2)	25	90	27.8(18.9, 38.2)
BSHC/BSOS	2	4	50.0(6.8, 93.2)	7	31	22.6(9.6, 41.1)
<b>Total</b>	<b>44</b>	<b>82</b>	<b>53.7(42.3, 64.7)</b>	<b>184</b>	<b>452</b>	<b>40.7(36.1, 45.4)</b>

# SECTION 5: PROVISION OF AN APPROPRIATE AND ACCEPTABLE SERVICE

## 5e First surgical treatment within 20 working days

### Description:

The time from when a woman receives her final diagnostic results to the date of her first surgical treatment.

### Target for women aged 50–69 years:


90% of women should normally receive their first surgical treatment within 20 working days of receiving their final diagnostic results.

**Table 5e.a: Proportion of women receiving first surgical treatment within 20 working days, 5 years (July 2009–June 2014), Māori and non-Māori women aged 45–49 and 50–69 years**

Lead provider	Māori			Non-Māori			Māori/Non-Māori ratio (95% CI)
	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)	
<b>45–49 years</b>							
BSWN	19	38	50.0(33.4, 66.6)	111	188	59.0(51.7, 66.1)	0.85(0.60, 1.19)
BSCM	6	29	20.7(8.0, 39.7)	24	105	22.9(15.2, 32.1)	0.91(0.41, 2.00)
BSAL	9	15	60.0(32.3, 83.7)	54	110	49.1(39.4, 58.8)	1.22(0.78, 1.93)
BSM	20	37	54.1(36.9, 70.5)	83	125	66.4(57.4, 74.6)	0.81(0.59, 1.12)
BSCtoC	18	31	58.1(39.1, 75.5)	71	98	72.4(62.5, 81.0)	0.80(0.58, 1.11)
BSC	9	13	69.2(38.6, 90.9)	73	132	55.3(46.4, 64.0)	1.25(0.84, 1.86)
BSSL	16	30	53.3(34.3, 71.7)	128	209	61.2(54.3, 67.9)	0.87(0.61, 1.24)
BSHC/BSOS	2	7	28.6(3.7, 71.0)	44	77	57.1(45.4, 68.4)	0.50(0.15, 1.64)
<b>Total</b>	<b>99</b>	<b>200</b>	<b>49.5(42.4, 56.6)</b>	<b>588</b>	<b>1,044</b>	<b>56.3(53.3, 59.4)</b>	<b>0.88(0.76, 1.02)</b>
<b>50–69 years</b>							
BSWN	67	125	53.6(44.5, 62.6)	495	772	64.1(60.6, 67.5)	0.84(0.70, 0.99)
BSCM	20	104	19.2(12.2, 28.1)	129	457	28.2(24.1, 32.6)	0.68(0.45, 1.04)
BSAL	12	30	40.0(22.7, 59.4)	208	411	50.6(45.7, 55.5)	0.79(0.50, 1.24)
BSM	118	189	62.4(55.1, 69.4)	433	666	65.0(61.3, 68.6)	0.96(0.85, 1.09)
BSCtoC	48	113	42.5(33.2, 52.1)	328	522	62.8(58.5, 67.0)	0.68(0.54, 0.85)
BSC	29	65	44.6(32.3, 57.5)	277	488	56.8(52.2, 61.2)	0.79(0.59, 1.04)
BSSL	30	53	56.6(42.3, 70.2)	618	962	64.2(61.1, 67.3)	0.88(0.69, 1.12)
BSHC/BSOS	10	16	62.5(35.4, 84.8)	206	349	59.0(53.7, 64.2)	1.06(0.72, 1.56)
<b>Total</b>	<b>334</b>	<b>695</b>	<b>48.1(44.3, 51.8)</b>	<b>2,694</b>	<b>4,627</b>	<b>58.2(56.8, 59.6)</b>	<b>0.83(0.76, 0.90)</b>

Ratios below one are unfavourable to Māori. Shaded boxes show confidence interval excludes target of 90% or more. Ratios in italics show a statistically significant difference between Māori and non-Māori.

**Figure 5e.a: Trends in the proportion of Māori and non-Māori women aged 50–69 years receiving first surgical treatment within 20 working days, by Lead Provider, July 2008–June 2014**



**Table 5e.b: Proportion of women receiving first surgical treatment within 20 working days, 5 years (July 2009–June 2014), Pacific and non-Māori non-Pacific women aged 45–49 and 50–69 years**

Lead provider	Pacific			Non-Māori non-Pacific			Pacific/Non-Māori non-Pacific ratio (95% CI)
	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)	
<b>45–49 years</b>							
BSWN	5	8	62.5(24.5, 91.5)	106	180	58.9(51.3, 66.2)	1.06(0.61, 1.84)
BSCM	3	24	12.5(2.7, 32.4)	21	81	25.9(16.8, 36.9)	0.48(0.16, 1.48)
BSAL	1	9	11.1(0.3, 48.2)	53	101	52.5(42.3, 62.5)	0.21(0.03, 1.36)
BSM	0	3	0.0(0.0, 70.8)	83	122	68.0(59.0, 76.2)	0.00(0.00, 1.85)
BSCtoC	1	1	100.0(2.5, 100.0)	70	97	72.2(62.1, 80.8)	1.39(0.22, 1.44) #
BSC	2	9	22.2(2.8, 60.0)	71	123	57.7(48.5, 66.6)	0.38(0.11, 1.32)
BSSL	1	2	50.0(1.3, 98.7)	127	207	61.4(54.4, 68.0)	0.81(0.20, 3.27)
BSHC/BSOS	0	1	0.0(0.0, 97.5)	44	76	57.9(46.0, 69.1)	0.00(0.00, 6.65)
<b>Total</b>	<b>13</b>	<b>57</b>	<b>22.8(12.7, 35.8)</b>	<b>575</b>	<b>987</b>	<b>58.3(55.1, 61.4)</b>	<b>0.39(0.24, 0.63)</b>
<b>50–69 years</b>							
BSWN	28	42	66.7(50.5, 80.4)	467	730	64.0(60.4, 67.5)	1.04(0.84, 1.30)
BSCM	14	74	18.9(10.7, 29.7)	115	383	30.0(25.5, 34.9)	0.63(0.38, 1.03)
BSAL	16	45	35.6(21.9, 51.2)	192	366	52.5(47.2, 57.7)	0.68(0.45, 1.02)
BSM	8	12	66.7(34.9, 90.1)	425	654	65.0(61.2, 68.6)	1.03(0.68, 1.54)
BSCtoC	4	6	66.7(22.3, 95.7)	324	516	62.8(58.5, 67.0)	1.06(0.60, 1.88)
BSC	8	22	36.4(17.2, 59.3)	269	466	57.7(53.1, 62.3)	0.63(0.36, 1.10)
BSSL	5	7	71.4(29.0, 96.3)	613	955	64.2(61.1, 67.2)	1.11(0.69, 1.78)
BSHC/BSOS	1	3	33.3(0.8, 90.6)	205	346	59.2(53.9, 64.5)	0.56(0.11, 2.79)
<b>Total</b>	<b>84</b>	<b>211</b>	<b>39.8(33.2, 46.8)</b>	<b>2,610</b>	<b>4,416</b>	<b>59.1(57.6, 60.6)</b>	<b>0.67(0.57, 0.80)</b>

Ratios below one are unfavourable to Pacific women. Shaded boxes show confidence interval excludes target of 90% or more. Ratios in italics show a statistically significant difference between Pacific and non-Māori non-Pacific women.

**Table 5e.c: Proportion of women receiving first surgical treatment within 20 working days, 2 years (July 2012–June 2014), total aged 45–49 and 50–69 years**

Lead provider	45–49 years			50–69 years		
	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)	First surgical treatment within 20 working days	Total number having surgery	% receiving first surgery within 20 working days (95% CI)
BSWN	39	86	45.3(34.6, 56.5)	202	375	53.9(48.7, 59.0)
BSCM	11	53	20.8(10.8, 34.1)	57	214	26.6(20.8, 33.1)
BSAL	20	47	42.6(28.3, 57.8)	75	178	42.1(34.8, 49.7)
BSM	37	63	58.7(45.6, 71.0)	248	398	62.3(57.3, 67.1)
BSCtoC	34	55	61.8(47.7, 74.6)	141	262	53.8(47.6, 60.0)
BSC	29	54	53.7(39.6, 67.4)	116	207	56.0(49.0, 62.9)
BSSL	63	116	54.3(44.8, 63.6)	286	482	59.3(54.8, 63.8)
BSHC/BSOS	17	40	42.5(27.0, 59.1)	100	163	61.3(53.4, 68.9)
<b>Total</b>	<b>250</b>	<b>514</b>	<b>48.6(44.2, 53.1)</b>	<b>1,225</b>	<b>2,279</b>	<b>53.8(51.7, 55.8)</b>

Shaded boxes show confidence interval excludes target of 90% or more.

**Figure 5e.b: Trends in the proportion of total women aged 50–69 years receiving first surgical treatment within 20 working days, by Lead Provider, July 2008–June 2014**

